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CHAPTER 1 
INTRODUCTION 
INTRODUCTION 
In the inmune system the function of specific antigenic recognition is 
associated with membrane bound receptor structures. The receptors con­
sist of several constant domains encoded by a multigene family. The an­
tigen specificity of these receptors is located within variable do­
mains, called idiotypes. The variable domains are generated by rearran­
gement of various genes. For the В lymphocytes the antibody molecule 
functions as antigen receptor and the antigen binding site is generated 
by the rearrangement of a single V, D, and J gene out of a cluster of 
these genes. On the Τ cell receptor similar rearrangements of Τ cell 
specific v, D, J genes take place In the formation of τ cell idioty­
pes. The mechanism of the formation of antigen specific binding sites 
is basically an at random process of combining gene elements. A further 
diversity of antigen binding specificity can be generated by somatic 
mutation. Because the generation of diversity of antigen specificity is 
based on an at random combination of gene elements and somatic muta­
tion , this process must inevitably also lead to the formation of auto­
reactive idiotypes within the entire spectrum of possible idiotypes. 
Therefore, a mechanism of self and non-self discrimination must be ope­
rative after the formation of idiotypes to abolish the autoreactivity. 
How this occurs within the immune system is unknown, possible mecha-
nisns are active suppression, deletion of autoreactive clones, or regu­
lation within the idiotype-anti idiotype network. Although we do not 
exactly know how autoreactive patterns are omitted, it is clear that 
the surveillance mechanism sometimes fails, since autoreactivity is 
present in a variety of diseases. It seems logical to assume that auto­
reactivity can be present at the level of Τ cells as well as at the le­
vel of В cells. At the time that the serology of autoimmunity was deve­
loped, analysis of Τ cell functions was technically impossible. The 
finding of a wide variety of autoantibodies associated with autoinmune 
diseases and the lack of knowledge regarding Τ cells has focused the 
attention on the В cell compartment and on the role of autoantibodies 
in the pathogenesis of autoimmunity. 
In some autoimmune diseases as e.g. thyreoiditis, and myastema gravis, 
tissue antigens which can react with autoantibodies are demonstrable at 
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the site of inflammation. In such cases a simple pathogenic mechanism 
of in situ binding of autoantibodies with a subsequent inflamnatory 
reaction, seems most plausible. However, in a wide range of autoimmune 
diseases deposits of autoantibodies and complement can be present in 
tissues, while tissue antigens reactive with these antibodies are not 
demonstrable. These findings have led to the hypothesis that circula-
ting immune complexes might be deposited in certain tissues and trigger 
a phlogogenic reaction. 
This thesis deals with a critical analysis of the concept, that deposi-
tion of circulating immune complexes plays a role in the induction of 
two autoimmune diseases, vz. rheumatoid arthritis (RA) and systemic lu-
pus erythematosus (SLE). 
Phlogogenic potential of immune complexes 
That circulating immune complexes may have phlogogenic potentials was 
illustrated for the first time in the classic experimental animal stu-
dies by the groups of Dixon and coworkers (1,2) and Germuth and cowor-
kers (3,4), using an experimental serum sickness model in the rabbit. 
In the acute, single shot serum sickness model an intravenous admini-
stration of a large amount of heterologous protein (mostly bovine serum 
albumin, BSA), induces production of antibodies which bind to the an-
tigen in the circulation, thus forming circulating immune complexes. As 
the amount of antibody increases, the immune complexes increase in 
size, activate complement and are eliminated rapidly from the circula-
tion by the mononuclear-phagocyte system. During this immune elimina-
tion phase, both antigen and antibody can be demonstrated in vessel 
walls and glomerular capillary walls. These deposits initiate, via com-
plement activation and leukocyte Chemotaxis, a severe, transient in-
flammatory reaction, resulting in a necrotizing vasculitis and prolife-
rative glomerulonephritis with proteinuria. In the chronic serum sick-
ness model continuous administration of smaller amounts of heterologous 
protein leads via similar mechanisms to histologically widely varying 
forms of glomerulonephritis, ranging from membranous to extracapillary, 
proliferative glomerulonephritis. The combined presence of antigen and 
antibody is a prerequisite for the local inflammatory reaction, however 
9 
the mechanisms that lead to the formation of the immune-complex at the 
site of the inflammation are far from clear. The fact that in both se-
rum sickness models immune complexes were detectable in the circulation 
has led to the general assumption that deposition of immune complexes 
formed in the circulation is the ma]or pathogenic mechanism for induc-
tion of vascular and glomerular inflammation. Based on the observations 
in this experimental animal model it was assumed that 80% of the cases 
of human glomerulonephritis are caused by similar mechanisms. However, 
in patients with primary glomerulopathy, circulating immune complexes 
are rarely detectable (5). 
Studies initially initiated by the groups of Hoedemaeker (6,7) and 
Couser (8,9) have shown that several forms of experimental glomerulone-
phritis, especially membranous glomerulopathy, can be caused by the in 
situ formation of immune complexes through antibody binding to intrin-
sic glomerular antigens or extrinsic, "planted" antigens. In passive 
Heymann's nephritis in the rat subepithelial deposits develop after ad-
ministration of heterologous antibodies to proximal tubular brush bor-
der antigens (6,9). Similar immune deposits can also be induced by al-
ternate perfusion of an isolated rat kidney with free BSA antigen fol-
lowed by anti-BSA antibody. In contrast to this, perfusion with pre-
formed BSA immune complexes failed to produce subepithelial immune de-
posits (10). Therefore, subepithelial immune deposits seem to occur 
predominantly as a result of in situ glomerular deposit formation. Me-
sangial and subendothelial deposits may occasionally result from depo-
sition of circulating immune complexes as indicated by several experi-
mental animal studies, but also this type of immune complex deposition 
may result from in situ formation (9). 
Although there is at present no conclusive evidence to document either 
in situ immune complex formation or deposition of circulating immune 
complexes in human glomerulonephritis, it seems likely that both mecha-
nisms are operative. Planting of antigen might explain for instance why 
in poststreptococcal glomerulonephritis, generally regarded as a proto-
type of glomerulonephritis caused by deposition of circulating immune 
complexes, streptococcal antigen can be found in the glomerular capil-
lary wall prior to the deposition of immunoglobulins (11). Moreover, in 
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patients with acute poststreptococcal glomerulonephritis circulating 
immune complexes are rarely found (5)· 
Assays for detection and quantification of circulating immune complexes 
The interest in the possible clinical significance of circulating 
immune complexes (CIC) has led to the development of an overwhelming 
amount of techniques to detect them. The majority of these techniques 
is not antigen specific and is based on physical properties of CIC or 
interactions of these complexes with complement components, rheumatoid 
factors, or cell surface receptors. An analysis of the various tech-
niques and their specificity and sensitivity will not be given here, 
since comprehensive reviews are available (5). We wíl only give a more 
detailed description of the two immune complex (1С) assays that we used 
in our study of CIC in RA and SLE sera. A comparative analysis carried 
out in 1978, under auspices of the WHO, revealed that six out of 18 as­
says tested, were able to discriminate between normal human sera and 
SLE sera, and between normal human sera and RA sera. The most widely 
used among these six assays are the Clq binding assay (ClqBA) and the 
Ra]i-cell assay (RCA) (12). The ClqBA is based on the fact that monome-
ric IgG or IgM only weakly bind Clq, while aggregated or complexed IgG 
or IgM bind Clq avidly. In the ClqBA radiolabeled free Clq is separated 
from Clq bound to 1С by differential precipitation with polyethylene 
glycol. The amount of precipitated Clq allows quantification of 1С 
(13). The RCA is based on the interaction of C3 split products bound to 
1С with C3 receptors on Ra]i cells. Ra]i cells are derived from a con­
tinuous lymphoblastoid cell line from a Burkitt's lymphoma, and they 
bear receptors for several complement components (mainly C3b, C3d, and 
Clq). Because these cells lack surface bound IgG and have few and only 
low-affinity Fc receptors, they are ideally suited for 1С measurements 
(14,15). The amount of 1С bound to Ra]i cells is quantitated by radio­
labeled anti-human immunoglobulin antibodies or radiolabeled staphylo­
coccal protein A. In the WHO comparative study the ClqBA yielded the 
highest incidence of positivity and measured the highest levels of 1С 
in RA sera, while the RCA gave the highest incidence of positivity and 
highest levels in SLE sera (12). 
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When we used the ClqBA on a wider scale for clinical purposes we were 
struck by the finding that binding levels in citrate plasma were consi­
derably higher than in simultaneously obtained serum specimens from the 
same individuals. The studies providing the explanation for this obser­
vation are given in chapter 2. 
immune complexes in rheumatoid arthritis 
Rheumatoid arthritis (RA), a systemic disease characterized by erosive 
polyarthritis, is generally associated with the presence of IgM or IgG 
anti-immunoglobulin antibodies (rheumatoid factor, RF) . The identifica­
tion with immunofluorescence of IgG and IgM together with complement 
components in rheumatoidsynovium points to immunological mechanisms in 
the pathogenesis of synovial lesions in RA. Isolation of immunoglobulin 
- RF complexes from RA synovial fluid, depressed complement levels in 
the synovial fluid of RA patients, and elution of RF from arthritic le­
sions indicate that formation of immune complexes is involved in the 
inflammatory reaction in the joints (16). 
Increased levels of CIC have been detected in RA sera especially with 
the fluid phase C1q binding assay (ClqBA) and the Raji cell assay. How­
ever, in a comparative analysis the ClqBA showed a much higher inci­
dence of positivity and higher levels of CIC in the same sera than 
other tests for measurement of CIC (12). Especially the difference be­
tween the ClqBA, in which Clq is bound in the fluid phase and precipi­
tated by polyethylene glycol, and the Clq solid phase assay is striking 
and puzzling. Moreover, in RA without extra-articular manifestations 
systemic complement activation is hardly ever present, despite the de­
monstration of complement binding 1С with the ClqBA. Because of this 
discrepancy we analyzed in detail why the ClqBA yields high levels of 
CIC in RA sera (chapter 3 ) . 
Immune complexes In systemic lupus erythematosus 
In contrast to primary glomerulopathy in which circulating inmune com­
plexes are infrequently detected, CIC are found in the majority of pa­
tients with secondary glomerulopathy due to SLE, especially when the 
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Raj i cell assay is used (5,12). This has led to the general assumption 
that CIC, especially DNA-anti DNA inmune complexes, are a prerequisite 
for the development of SLE glomerulonephritis. If one, however, scruti-
nizes the littérature for evidence to support this central dogma, cru-
cial pieces of evidence are lacking. 
Several studies have shown beyond any doubt the presence of high affi-
nity anti-DNA antibodies and complement factors in eluates from kidneys 
with active SLE glomerulonephritis (17-19). However, the presence of 
the presumed antigen DNA in the circulation, in circulating immune com-
plexes, or in glomerular deposits has not been proven unequivocally. 
Studies of Steinman (20,21) have shown convincingly that there is, like 
in normal subjects, no free DNA in the circulation of patients with ac-
tive SLE (except for patients with cerebral SLE or systemic vasculi-
tis) . All other studies claiming the presence of free DNA in the circu-
lation of SLE patients have been done on serum samples, in which appa-
rently the DNA is generated during the clotting, since it can be found 
in the same concentrations in normal sera. Also, if DNA is administered 
to SLE-mice, it is rapidly cleared from the circulation and does not 
deposit in diseased tissues (22,23). Furthermore, there is no good evi-
dence for the presence of circulating complexes consisting of DNA and 
anti-DNA antibodies. Izui et al (24), using four different radioimmuno-
assays, were unable to detect substantial amounts of such complexes in 
SLE sera. This study confirmed a previous study in which anti-DNA bin-
ding in SLE sera did not increase after DNAse treatment indicating that 
there was no DNA bound to anti-DNA antibodies (25). Most astonishing is 
that the contention that DNA anti-DNA complexes (either deposited from 
the circulation or formed in situ) are responsible for the development 
of SLE glomerulonephritis, is generally accepted without the formal 
proof of physical isolation of DNA from diseased glomeruli. The only 
identification of DNA in SLE kidneys comes from immunofluorescence stu-
dies in two out of seven kidney specimens in which anti-DNA antibodies 
were used as a probe (17,18). However, positive staining was only ob-
served after treatment of tissue sections with buffers with high salt 
concentrations. In these studies it was not excluded that DNA was re-
leased from cells by the high salt condition. Although anti-DNA antibo-
dies are undoubtedly involved in the pathogenesis of SLE glomerulone-
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phritis, these anti-DNA antibodies are probably not trapped in the kid-
ney via deposition of circulating DNVanti-DNA complexes. If DNA/anti-
DNA immune complexes are not present in SLE sera, what then causes the 
high incidence of positive results in the Raj i cell assay. This is one 
of the questions which was studied in this thesis (Chapter 4 ) . 
The recent discovery that monoclonal and polyclonal anti-DNA antibodies 
can crossreact with other molecules such as cardiolipin and other phos-
pholipids (26-28) prompted us to investigate whether other molecules 
such as glycosaminoglycans could serve as antigens for anti-DNA antibo-
dies. We were especially interested in chondroitin sulphate and hyalu-
ronic acid since these molecules are abundantly present in connective 
tissues of skin and joints, which are frequently involved in SLE. In 
the kidney heparan sulphate is the major glycosaminoglycan present in 
the glomerular basement membrane. It has a major role in the mainte-
nance of the charge-selective barrier, and is probably also responsible 
for the integrity of the size-selective barrier (29). The results of 
these studies are presented in chapter 5 and 6. 
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The interference of fibrinogen and heparin 
with the determination of circulating immune complexes 
in the Clq-binding assay 
P FAABER.P J A CAPEL&R A Ρ KOENE Department ofMedicine Dwmonof 
Nephrology University of Nijmegen, The Netherlands 
( Accepted for publication 20 March 1981) 
S U M M A R Y 
When citrate plasma and serum of the same individual were tested simultaneously in the 
Clq-binding assay (ClqBA), binding levels in plasma were found to be 90-400% higher 
than in serum The difference in 12SI-Clq binding was due to the presence of fibrinogen in 
plasma It was shown that complex formation between fibrinogen and '25I-C Iq occurs and 
that this complex precipitates in the presence of polyethylene glycol, leading to the false 
positive results in the ClqBA When heparin plasma was used in the assay, heparin itself 
also induced an increase in l25l-CI q binding that was not based on the presence of immune 
complexes The eflecl of both fibrinogen and heparin could be inhibited by addition of 
protamine sulphate Therefore, pretreatment of plasma with protamine sulphate makes it 
possible to use plasma samples for a reliable determination of Clq-binding levels 
However, serum that is well clotted should be used preferentially 
INTRODUCTION 
The role ofcirculating immune complexes as pathogenic agents in a variety ofdiseases is becoming 
well established (Zubler & Lambert, 1978, McCluskey, Hall & Colvin, 1978) One of the methods 
that is widely applied to detect such complexes in human sera makes use of the binding of Clq to the 
immune complexes Dependent on the test system used, several components that can interact with 
Clq, such as DNA, heparin and bacterial and phage products, may cause false positive results in 
these tests (Sobel.Bokisch&Muller-Eberhard, 1975) Zubler etal ( 1976) have described a modified 
Clq-binding assay (ClqBA) in which radiolabelled Clq bound to the immune complexes is 
precipitated by polyethylene glycol (PEG) In this test the influence of DNA is minimal 
Furthermore, bacterial lipopolysacchandes would not exhibit a strong binding activity, probably 
because DNA and LPS are quite soluble in PEG The presence of heparin, however, results in the 
precipitation of ,2SI-Clq in the absence of immune complexes (Woodroffe et at, 1977) This action 
of heparin is not related to its anticoagulant effect since its interference with the ClqBA was 
demonstrated by its addition to serum In this study we have compared the Clq-binding levels in 
plasma and serum and we present evidence that the fibrinogen present in plasma leads to false 
positive results in the ClqBA, independently of the effect of heparin We have, furthermore, devised 
a modified assay which obviates this problem and which makes it possible to use plasma in the 
ClqBA 
Correspondence Ρ Faaber, Department of Medicine, Division of Nephrology, University of Nijmegen, The 
Netherlands 
0OO9-9104/81/09OO-059OSO2 00 © 1981 Blackwell Scientific Publications 
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CIC determination in the ClqBA 
MATERIALS A N D METHODS 
ClqBA. Clq was isolated from fresh serum according to Yonemasu & Stroud (1972). The 
isolated Clq was radiolabelled with Na l 2 5I (Radiochemical Centre, Amersham, UK) using the 
chloramine Τ method (Hunter & Greenwood, 1962) resulting in a specific activity of 2 ¿iCi/pg Clq. 
Free iodine was separated from protein-bound label by Sephadex G-25 chromatography. Further 
purification was obtained by isokinetic sucrose-gradient centrifugation [5-33% w/v sucrose 
dissolved in phosphate-buffered saline (PBS) containing 1 % w/v bovine serum albumin (BSA)]. The 
1 IS peak was fractionated from the gradient after centrifugation in an SW41 rotor for 16 hr at 
37,000 r.p.m. at 4°C. The ClqBA was performed as described by Zubler el al. (1976). When no 
serum was used in the ClqBA, the test-tubes were first coated overnight with 10 mg/ml BSA, 
dissolved in PBS. This prevented non-specific absorption of Clq to the walls of the tubes. Serum 
from 17 healthy individuals, without detectable circulating immune complexes, was pooled and 
used as standard control serum (binding levels of less than 5% were considered as normal). 
Polyethylene glycol 6000 (PEG) was purchased from BDH Chemicals Ltd, Poole, England. 
Plasma and serum samples. To obtain plasma, blood was collected in glass tubes containing 
sodium citrate 3-8%, pH 8 5 (final concentration 10% v/v), centrifuged at 2,000^ for 5 min. Serum 
was obtained from blood after clotting in glass tubes at room temperature for 3 hr and subsequent 
centrifugation for 5 min at 2,000 g. Plasma and serum samples were stored at - 20 C. 
Fibrinogen. Human fibrinogen (B grade) was purchased from Calbiochem, California, USA, 
and radiolabelled with Na m I by the chloramine Τ method. The specific activity was 2-5 μ€ι/μ%. 
Prolamine sulphate. This was purchased from NOVO Industri A/S, Copenhagen, Denmark. 
Heparin was purchased from Organon Teknika BV, Oss, Holland. 
Clotting factors. Human thrombin was obtained from the Central Laboratory of the 
Netherlands Red Cross Blood Transfusion Service and plasminogen was obtained from AB KABI, 
Stockholm, Sweden. 
Streptokinase. This was purchased from Behringwerke AG, Marburg, Germany. 
RESULTS 
Interference of fibrinogen with the ClqBA 
Plasma and serum samples from four patients collected at the same time were tested in the ClqBA. 
To exclude the influence ofheparin on the assay, sodium citrate was used as an anticoagulant. Fig. 1 
shows that in each patient the С1 q-binding level in plasma was higher than that in serum. This holds 
true for both the positive sera (patients 1,2 and 3) and the negative serum (patient 4). The increase of 
the Clq binding in plasma as compared to serum ranged from 90 to 400% Addition of sodium 
Blood sample 
Fig. 1. Comparison of the 125I-Clq-bmding levels in plasma (β) and serum (a) of four patients. 
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citrate to the standard serum in a concentration similar to that in the plasma samples did not result 
in a rise in Clq-binding activity, which shows that sodium citrate was not responsible for the 
observed increase in the plasma 
The influence of several proteins of the clotting system on the ClqBA was tested by addition of 
these proteins to the standard serum Addition of human thrombin, plasminogen or plasmin 
(obtained by converting plasminogen to plasmin with streptokinase) had no effect on the outcome 
of the test However, fibrinogen in a concentration ranging from 0 5 to 2 5 mg/ml serum resulted in a 
dose-dependent increase in Clq-binding levels ranging from 7% for the lowest concentration of 
fibrinogen to 21% at the highest concentration We then tested whether the fibrinogen 
concentration m the plasma samples was high enough to cause the observed increase in С lq-binding 
levels In the plasma samples of the four patients the fibrinogen concentrations, as determined by 
radial immunodiffusion (Mancini, Carbonara & Heremans, 1965), ranged from 2 5 to 3 5 mg/ml In 
the sera of these patients no fibrinogen was detectable Addition of purified fibrinogen to these sera 
in a final concentration of 2 5 mg/ml resulted in increased Clq-binding levels which were 
comparable with those found in the plasma samples This indicates that the presence of fibrinogen 
itself might be sufficient to explain the increased Clq binding observed in the plasma 
The interference of fibrinogen with the ClqBA might be explained by a direct interaction 
between fibrinogen and Clq, resulting in the formation of a complex that can be precipitated by 
PEG To test this, mI-fibnnogen was added to the standard serum in a concentration ranging from 
0 5 to3 mg/ml serum Thereafter, the binding assay was carried out, but in the absence of'251-Clq 
This resulted in a dose-dependent precipitation of l25I-fibrinogen ranging from 6% for the lowest 
concentration to 22% for the highest concentration of 12SI-fibrinogen In the absence of serum no 
fibrinogen was precipitated by PEG 
These experiments did not answer the question whether fibrinogen binds directly to Clq or 
whether serum components other than Clq are involved Therefore, we studied the interaction of 
Clq and fibrinogen in the absence of serum When l25I-Clq (200 jig/ml) or l25I-fibrinogen (2 5 
mg/ml), dissolved in PBS, were separately tested in the binding assay, the percentage of binding was 
5% However, combined addition of similar concentrations of mI-Clq and unlabelled fibrinogen 
resulted in a binding of 20%, demonstrating that in PEG, complex formation between labelled С1 q 
and fibrinogen occurs without serum components 
Finally, we studied whether Clq can interact directly with fibrinogen and form a complex in the 
absence of PEG For this purpose l2SI-Clq was incubated with fibrinogen (final concentration 2 5 
mg/ml serum) and serum (50 μ\) in the presence of 100 μ\ 0 2 M EDTA, pH 7 5, for 30 mm at 37°C 
and then analysed on a 5-33% w/v isokinetic sucrose gradient The gradient was spun for 16 hr at 
37,000 г ρ m at 4 C The radiolabel was recovered as a single peak in the 11S region demonstrating 
that, in the absence of PEG, no complex formation had occurred Taken together, these results 
suggest that PEG promotes an association of 125I-CI q and fibrinogen, which results in a precipitable 
complex 
Influence of heparin and protamine sulphate on the ClqBA 
In routine clinical practice, plasma is usually obtained by collecting blood samples in hepann and it 
is known that heparin can also interfere with the ClqBA To test its influence, amounts of hepann 
ranging from 0 01 to 5 mg/ml were added to sera that reacted either positively or negatively in the 
ClqBA Both in the positive serum and in the negative serum, increase in Clq-binding levels was 
dependent on the concentration of heparin (Fig 2) Protamine sulphate, which antagonizes the 
anticoagulant activity of heparin, was then tested for its capacity to inhibit the С1 q-binding activity 
of heparin First, we studied the effect of protamine sulphate itself on the ClqBA in a positive and a 
negative serum Up to a concentration of 2 mg/ml, protamine sulphate did not change the 
Clq-binding activity of these sera 
The addition of protamine sulphate to a previously negative serum that, after addition of 0 32 
mg/ml of heparin, had developed a binding capacity of 60%, resulted in a gradual decrease of the 
Clq-binding level dependent on the protamine sulphate concentration (Fig 3) Thus the direct 
effect of heparin on the assay could be blocked by protamine sulphate Subsequently we studied 
whether protamine sulphate can also interfere with the binding of fibrinogen to Clq in the presence 
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CIC determination in the ClqBA 
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Fig. 2. Changes in С1 q BA levels by addition of heparin in increasing amounts to a positive serum (o—o) or to a 
negative serum (·—·) 
Fig. 3. Blockade of the effect of hepann in the ClqBA by protamine sulphate Increasing amounts of protamine 
sulphate were added to a ClqBA-negative serum which became ClqBA-positive by the addition of 0 32 mg/ml 
of hepann 
of PEG Therefore, two ClqBA-negative sera were supplemented with fibrinogen to a final 
concentration of I S and 2 S mg/ml serum resulting in an increased Clq binding of IS and 21% 
respectively, after addition of protamine sulphate (2 mg/ml) the ClqBA again became negative in 
both sera 
These data suggest that heparin plasma, after treatment with an excess of protamine sulphate, 
can be used in the ClqBA We therefore compared the binding levels of serum samples, positive or 
negative in the ClqBA, and heparin plasma of the same individuals, before and after addition of 
excess protamine sulphate to the plasma (final concentrations 1 and 2 mg/ml) The plasma samples 
that contained protamine sulphate were first incubated at 37°C for 30 min to convert fibrinogen to 
fibrin by the intrinsic clotting mechanism Fibrin was then removed by centnfugation for 5 mm at 
2,000 g The supernatant was tested m the ClqBA As shown in Fig 4 the binding levels in the 
plasma samples decreased as a consequence of the addition of protamine sulphate to values 
comparable to those in the corresponding sera This holds true for both the patients with a negative 
and a positive ClqBA 
100 
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20 
*fa_ ft^ ·"'-' fcn. 1 2 3 4 
Blood sample 
Fig. 4. Effect of addition of protamine sulphate on the l25I-Clq binding levels ofhepann plasma in comparison 
to the levels in corresponding serum samples (a) Heparin plasma, (•) heparin plasma + protamine sulphate, I 
mg/ml, (a) hepann plasma + protamine sulphate, 2 mg/ml, (•) serum 
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DISCUSSION 
Our results show that there are considerable differences in the levels of '"I-Clq binding in plasma 
and serum samples from the same individual In accordance with the literature (Woodroffe e ι al, 
1977) we found that this can be caused by an interaction between Clq and heparin However, in 
plasma from blood collected in sodium citrate the Clq-binding levels were also considerably higher 
than in serum, whereas addition of sodium citrate to serum did not change the Clq-binding level 
This indicated that factors of the clotting system were responsible for the observed effect Indeed, 
addition of fibrinogen to serum resulted in an increased binding level of l25I-Clq, the percentage of 
binding being dependent on the concentration of fibrinogen It was possible to reconstitute the 
serum samples with fibrinogen to levels equivalent to those in the plasma samples, indicating that 
fibnnogen alone caused the rise in Clq-binding activity Studies on the mechanism of this 
phenomenon revealed that the interaction is caused by direct binding of fibrinogen to Clq This 
complex formation can occur in the absence of other serum components We found in these latter 
experiments that it was important to use test tubes that were coated with BSA to avoid adsorption 
of the labelled proteins to the walls of the tubes By using isokinetic sucrose gradients it was shown 
that there is no direct interaction between Clq and fibnnogen in the absence of PEG The nature of 
the binding between Clq and fibrinogen is probably based on weak protein-protein interactions 
The fact that protamine sulphate blocked this binding indicates that the forces which are leading to 
a complex that is stabilized by PEG might have an electrostatic nature 
Our findings stress the importance of using serum samples obtained from thoroughly clotted 
blood in the ClqBA However, it is not always possible to obtain well-clotted blood For example, 
when immune complexes are removed from the circulation by plasmapheresis it is necessary to 
administer anticoagulants to the patient in order to prevent clotting in the extracorporeal circuit 
Therefore, blood samples taken during, or immediately after the plasma exchange, may have a false 
positive Clq binding The same holds for blood of patients with disturbances of the clotting system 
in whom remnants of fibrinogen in the serum may interfere with the assay For these special cases we 
advise pretreatment of samples with excess of protamine sulphate since we showed that this 
compound antagonizes the interaction of both hepann and fibrinogen with labelled Clq, without 
interfering with the interaction of l2SI-Clq and circulating immune complexes 
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ABSTRACT 
Circulating inmune complexes (С.I.С), as detected by the Clq binding 
assay (ClqBA) in sera from patients with rheumatoid arthritis (RA) were 
not demonstrable on analysis of these sera by ultracentrifugation on 
sucrose gradients. This discrepancy could be explained by the finding 
that Polyethylene glycol 6000 (PEG) used in the ClqBA to separate free 
radiolabelled Clq from complex bound Clq, increased the avidity of 
rheumatoid factor (Rf) resulting in the formation of Clq binding Rf-
IgM-IgG complexes. Addition of purified Rf-lgM to normal human serum 
generated a positive ClqBA in a dose dependent way. The increased com­
plex formation between Rf-lgM and IgG by PEG was also demonstrated in 
an enzymelinked immunosorbent assay and with sucrose gradients, where 
complexes became detectable when PEG was present. On the other hand 
Rf-IgM-IgG-Clq complexes obtained from the ClqBA dissociated upon remo­
val of PEG. We conclude that high amounts of immune complexes, detected 
in RA sera by the ClqBA, are at least partly the result of in vitro 
complex formation between Rf-lgM and IgG. Therefore the results of this 
assay do not reflect the situation in the circulation in vivo. 
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INTRODUCTION 
Autoantibodies are regularly detected in sera from patients with rheu-
matoid arthritis (RA)· The most common autoantibody in rheumatoid fac-
tor (Rf), which is directed against constant region determinants of 
IgG. As a consequence circulating immune complexes (C.I.C.) can be ex-
pected to be present in RA and they might play a pathogenic role in 
this disease· Indeed most RA-sera react positively in assays devised to 
detect inmune complexes1. The most commonly used test, the Clq binding 
assay (ClqBA), which is based on the binding of Clq to immune com-
plexes2, is positive in 83% of RA sera1. Despite the demonstration of 
complement binding complexes, complement levels are usually normal in 
such sera3,4. Because of this discrepancy we analyzed RA sera for the 
presence of immune complexes by ultracentrifugation on sucrose gra-
dients. We report here that with this technique immune complexes were 
not demonstrable in these sera. However, the addition of Polyethylene 
glycol 6000 (PEG) to these sucrose gradients induced a clearly detec-
table immune complex formation in these originally negative sera. A 
further analysis of the ClqBA showed that this test predominantly de-
tects immune complexes in RA sera formed under the assay conditions by 
PEG, due to an increase of antibody avidity. 
MATERIALS AND METHODS 
Sera. Blood samples were obtained from patients who fulfilled at least 
five criteria of the American Rheumatism Association for definite RA^. 
All patients had active disease. The blood was allowed to clot at room 
temperature for 3 h and subsequently centrifuged for 5 min. at 
2,000 g. The serum samples were stored at -70° and used only once. 
Isokinetic sucrose gradient, isokinetic sucrose gradients were prepared 
by addition of 33% w/v sucrose in phosphate buffered saline (PBS) to 5% 
w/v sucrose in PBS in a mixing chamber with a constant volume. Gra-
dients were centrifuged at 36,000 rpm in a SW40 rotor (Beekman L5-65 
centrifuge) for 16 h at 4°C. After fractionation of the gradients, the 
tubes were thoroughly washed with one fraction volume PBS to resuspend 
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precipitated high molecular weight material from the bottom. When ra­
dioactive tracers were used, the 125i-material in the precipitate was 
measured by counting the bottom of the tube after fractionation of the 
gradient. When PEG was present in the gradients the sucrose was dis­
solved in a 0.1 M Borate buffer pH 8.3 containing 5% PEG, 0.05% Tween 
20, and 17 mM EDTA. Due to a different viscosity of these gradients, 
resulting in a slower sedimentation rate, these gradients were spun at 
40,000 rpm for 18 h at 4°C. 
С1qBA. The assay was performed as described by Zubler et al2, when no 
serum was used in the ClqBA, the test tubes were first coated overnight 
with 10 mg/ml bovine serum albumin (BSA), dissolved in PBS. This pre­
vented non-specific absorption of C1q to the walls of the tubes. 
Complement and immunoglobulin levels. The concentrations of complement 
components and iranunoglobulins were measured nephelometrically with an-
tisera purchased from Kallestad (U.S.A.). Haemolytic complement activi­
ty (CH50) was measured according to Mayer^. 
Rheumatoid factor. An IgM rheumatoid factor containing fraction was 
isolated from RA positive serum by ultracentrifugation on an isokinetic 
sucrose gradient (same conditions as mentioned above). The 19S peak was 
pooled, dialyzed against PBS, and concentrated to twice its original 
volume to avoid aggregation. in this fraction IgG could not be detected 
nephelometrically. The Rf-titer was determined by latex agglutination 
(human IgG-coated latex particles were purchased from Behnngwerke AG/ 
Marburg, Germany). The sera were diluted in 2-fold steps in 0.1 M gly­
cine buffer, pH Θ.2, containing 0.1 M NaCl. The starting dilution of 
the sera was 1:10. For the determination of IgM-Rf in the gradient 
fractions an enzyme-linked immunosorbent assay (Elisa) was used'. 
Human immunoglobulins. Human IgG (Miles Laboratory, Inc. U.S.A.) was 
radiolabelled8 with Na^Sj. This 125i-igG was further purified by iso­
kinetic sucrose gradient centrifugation (same conditions as mentioned 
above). 
Enzyme-linked immunosorbent assay with PEG. To study the influence of 
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PEG on the binding characteristics of IgM-Rf, microtiter plates were 
coated with 50 ng rabbit IgG/well, followed by 2% BSA in PBS containing 
0.05% Tween 20. Twofold dilution series of the IgM fractions of RA sera 
or control sera were incubated in the presence of different PEG concen­
trations ranging from 1-3% w/v. The plates were washed with 0.1% BSA in 
PBS containing 0.05% Tween 20 and the appropriate PEG concentration. 
Bound IgM-Rf was determined with peroxidase conjugated anti human IgM 
(Miles) in a 1/500 dilution in 1% BSA in PBS and in the absence of 
PEG. The Elisa was developed with 5-aminosalicylic acid and the absorp-
tion was measured at 450 nm with a Titertek Multiskan. 
RESULTS 
Sucrose gradient analysis of RA sera. We analyzed C1qBA positive sera 
(range between 10-80% Clq binding activity) of 10 RA patients who had 
normal complement profiles as measured by C3, C4, factor В levels, and 
CH50 titer. Immune complexes which are thought to be present in these 
RA-sera were first determined by their size on sucrose gradients. To 
that end 0.4 ml of serum was layered on the gradients. After centrifu-
gation IgM, IgG, and IgA concentrations of each gradient fraction were 
measured nephelometrically. IgM-Rf activity was measured by Elisa. A 
representative example of the analysis, given in Fig.1, shows the ab­
sence of immune complexes composed of IgM-Rf and IgG. The protein pro­
files obtained with the 10 RA-sera were fully comparable with those of 
5 ClqBA negative, Rf negative human sera. The lower detection limit of 
the nephelometric assay was calculated and amounted to 10 yg/ml for IgG 
in the gradient fractions. Thus, if stable IgG containing immune com­
plexes were present their IgG concentration must have been below this 
detection level. The same sera were tested in the ClqBA. In this assay 
immune complex-bound 125i-ciq is separated from free 125i-ciq by the 
addition of 3% PEG which precipitates the immune complexes. The amount 
of IgG precipitated in the ClqBA was determined by radial immuno-diffu­
sion and it ranged in the 10 RA-sera from 0.1 to 3.2 mg/ml. In 5 normal 
human sera (NHS) only 0.08 +_ 0.04 mg/ml IgG was precipitated. Thus, the 
concentration of immune complexes in RA-sera, as measured in the ClqBA, 
appeared to be at least 10 times higher than one would have expected on 
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Fig. 1. Determination of large sized IgG containing complexes in ClqBA 
positive RA-serum by ultracentrifugation on a sucrose gra­
dient. The IgM, IgA, and IgG profiles were determined nephelo-
metrically and Rf activity was measured by an enzyme-linked im­
munosorbent assay. 
the basis of determinations with sucrose gradients. These conflicting 
findings could be explained by dissociation of the complexes during 
ultra-centrifugation on the one hand and formation of complexes under 
ClqBA conditions on the other. This latter possibility was supported by 
our findings of a close correlation between the Clq binding activity of 
the RA-sera and their Rf activity as measured by latex agglutination, 
suggesting that in both tests the same variable is measured (Fig.2). 
Formation of the immune complexes in the ClqBA might be caused by the 
presence of PEG that is known to enhance weak protein-protein interac­
tions9. Therefore, we analyzed the role of PEG in the ClqBA. 
Dissociation of ^^l-Clg from Rf-lgG complexes. The precipitates ob­
tained from 8 RA-sera in the ClqBA were resuspended in PBS containing 1 
mg/ml BSA and analyzed on sucrose gradients. In each case all the 
IZ^I-Ciq was recovered as a single peak in the IIS region. In order to 
recreate the original conditions of free antigen and antibody, the 
Rf activity 
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Fig. 2. Comparison of Rf and ClqBA activity in RA sera. Rf activity 
was determined by latex agglutination. 
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Fig. 3. Sedimentation of 125i-ciq in sucrose gradients. 
A. 125i-ciq containing precipitate from an RA serum obtained 
in the ClqBA and resuspended in the original serum (*-*). 
Control experiments with 125i-ciq added to the untreated 
RA-serum (·-·). 
B. 1 2 5I-C1q incubated with RA serum (*-*) or NHS (·-·) in the 
presence of PEG and analyzed on sucrose gradients 
containing 5% PEG. 
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C1qBA precipitates were resuspended in the original serum instead of 
BSA/PBS and subsequently analyzed on sucrose gradients. Under these 
circumstances 125l-ciq was also recovered as a single IIS peak 
(Fig.ЗА). This demonstrated that the binding of labelled Clq could be 
reversed by removal of PEG. Conversely, when an RA-serum or a normal 
human serum was incubated with 125i-ciq in the presence of 5% PEG and 
then analyzed on sucrose gradients containing 5% PEG, 80% of the 125i_ 
Clq was pelleted in the case of the RA-serum, whereas with NHS the 
125i-ciq was recovered as an IIS peak (Fig.3B). 
Formation and dissociation of Rf-125I-IgG complexes. After having ana­
lyzed the influence of PEG on the interaction of Clq with the IgM-Rf-
IgG complexes we studied its influence on complex formation between pu­
rified IgG and IgM-Rf. IgM from NHS was used as a control. 200 μΐ Rf or 
control IgM were incubated with 200 yl 7S 12^I-IgG (20 mg/ml) in the 
presence of 5% PEG for 1 h at 4°C and subsequently analyzed on sucrose 
FRACTION NUMBER FRACTION NUMBER 
Fig.4A. Complex formation between purified Rf-IgM and 1 2 5I-IgG, ana­
lyzed on sucrose gradients in the absence (•-•) or in the pre­
sence of 5% PEG (·-·). 
4B. Absence of complex formation between purified IgM from NHS and 
125i-igG, analyzed on sucrose gradients containing 5% PEG. 
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gradients in the presence or absence of 5% PEG. The results given in 
Fig. 4 show that, in the presence of PEG, IgG formed complexes with Rf 
(Fig.4A), but not with control IgM (Fig.4B). When PEG was absent from 
the gradients, complexes were not formed (Fig.4A). The sedimentation 
profile of 125i_igG
 Was slightly different in PEG containing gradients, 
but this was caused by the increased viscosity of the PEG-gradients. 
Another way to study the induction of complex formation by PEG was the 
binding of purified IgM-Rf or of control IgM to coated IgG as measured 
by the Elisa technique. Fifty ng rabbit IgG was coated per well. At 
this antigen concentration suboptimal Rf binding occurred which enabled 
us to measure the influence of PEG on Rf binding. As shown in Fig.5, 
PEG enhanced the binding of Rf to IgG in a dose dependent way. 
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Fig. 5. The influence of various concentrations of PEG (•-• 0%; ·-· 
1%; *-* 2%; •-• 3%) on the binding of Rf to coated IgG measur­
ed in an enzyme-linked immunosorbent assay in comparison with 
the IgM fraction of NHS in the presence of 3% PEG (»-») . 
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Pig. 6. Generation of ^Sj-ciq binding activity in ClqBA negative nor­
mal human serum (NHS) by addition of Rf. if no serum was used, 
test samples for the ClqBA were supplemented with PBS, con­
taining 10 mg/ml BSA, to a final volume of 100 μΐ before the 
addition of 50 ng 125I-C1q and PEG. 
Clq binding activity in normal human serum after addition of purified 
Rf. To show that Rf is complexed by PEG in the ClqBA, we added the Rf 
containing fraction to a ClqBA negative serum and subsequently tested 
this in the ClqBA. Rf of the IgM class that had been partially purified 
by ultracentrifugation of an RA, ClqBA positive serum, was added to a 
normal human serum. Fig.6 shows that the ClqBA negative serum acquired 
Clq binding activity in a dose dependent way upon addition of the Rf 
fraction. When the Rf fraction was tested in the absence of serum the 
ClqBA was negative. 
DISCUSSION 
Our results show that the binding of IgM-Rf to IgG is extremely labile 
in vitro. The amounts of immune complexes measured in the ClqBA can 
range in the tested sera from 0.1 to 3.2 mg/ml, whereas sucrose gra­
dient analysis shows that the concentration, measured by IgG content 
must be lower than 10 yg/ml, which was the detection limit for IgG in 
our nephelometric assay. Thus, the concentration of immune complexes in 
34 
the ClqBA appeared to be at least 10 times higher than those measured 
by sucrose gradient analysis. We have found several arguments to sup-
port the assumption that the ClqBA overestimates the in vivo concentra-
tion of circulating immune complexes in the RA-sera. An indirect indi-
cation is our finding of a close correlation between the Rf titer and 
the ClqBA activity of RA-sera. This accords with most reports in the 
literature1,10,11 and is in line with the idea that free Rf can become 
complexed to IgG under the assay conditions. Evaluation of these condi-
tions gave further support to this hypothesis. Protein-protein interac-
tions can be augmented by PEG, a phenomenon which is often used in 
classical immunoprecipitation studies to increase complex formation. 
Interference of PEG with complex formation was found to occur at two 
levels. First, we showed that the stable binding of Clq to the immune 
complexes was PEG dependent. When the antigen-antibody-Clq complexes, 
present in the ClqBA precipitates, were resuspended in PBS or in the 
original sera and subsequently analyzed on sucrose gradients in the ab-
sence of PEG, Clq dissociated from these complexes. These results are 
in agreement with the findings of Hack et al 1 2. Second, we found evi-
dence that PEG can induce the formation of complexes between IgM-Rf and 
7S ^Sj-igG, which are detectable by sucrose gradient ultracentrifuga-
tion in the presence of PEG. Increased complex formation by PEG was al-
so suggested by our findings that, in the Elisa, PEG induced a dose de-
pendent increase of the binding of IgM-Rf to coated IgG. The assumption 
that a great majority of the complexes detected in the ClqBA had formed 
in vitro is borne out by the findings of ourselves and others13, that 
addition of purified IgM-Rf (which itself was ClqBA negative) to a 
ClqBA-negative normal human serum resulted in a positive ClqBA in a 
dose dependent way. 
On the other hand we were not able to demonstrate IgG containing com-
plexes with sucrose gradient ultracentrifugation. These results are in 
apparent contrast with a previous report wherein RA sera were first se-
parated on sucrose gradients and the fractions subsequently tested in 
the C1qBA3# positive binding was found in the 10 to 30S region sugges-
ting the presence of inmune complexes. However, before the gradient 
fractions were tested in the ClqBA, normal human serum was added to ob-
tain satisfactory protein concentrations. Free IgM-Rf must have been 
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present in the high gradient fraction. As we have shown, addition of 
NHS to an Rf fraction that by itself is ClqBA negative leads to a posi-
tive reaction in the ClqBA, thus simulating the presence of immune com-
plexes. We have not performed ClqBA assay on the high gradient frac-
tions in our study because the IgG concentration of those fractions was 
lower than 10 yg/ml, which is far below the detection limit of the 
ClqBA (50 pg/ml of aggregated IgG). 
The absence of immune complexes in the gradient fractions does not 
prove that these were not present in the original serum, because it is 
likely that dissociation of immune complexes of low avidity will occur 
by the dilution of the sera on the gradients. This problem can be cir-
cumvented by analytical ultracentrifugation. Indeed, in RA sera with 
high concentrations of Rf soluble 22S complexes have been found with 
this technique^. Therefore we may conclude, that immune complexes are 
probably present in the circulation of RA-patients, but that the ClqBA 
overestimates their concentration. 
There are other arguments suggesting that the ClqBA is not a reliable 
test to measure inmune complexes in RA-sera. In a WHO study, in which 
18 methods for the detection of immune complexes were compared, only 
six were able to discriminate between sera of patients with RA and nor-
mal human control sera^. Five of the 18 assays were based on C1q and of 
these only the ClqBA was discriminatory. Of the four negative tests the 
Clq solid phase assay merits separate discussion. The negative result 
with this test in the WHO study is in agreement with two other re-
ports13/15f wherein no correlation was found between the amounts of 
circulating inmune complexes and the IgM-Rf. On the other hand, there 
is one study in which immune complexes were detected with this assay. 
The amount of complexes correlated significantly with the Rf-titers11. 
A possible explanation for this discrepancy might be found in differen-
ces of the test conditions. In the last mentioned study BSA was used as 
final coating, whereas in the other studies gelatin was used in place. 
We have found that small amounts of bovine immunoglobulins, which are 
often present in BSA preparations, can become bound to the test tubes 
and can serve as antigen for IgM-Rf giving a false positive result. 
Therefore, the purity of the bovine albumin preparation used in this 
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assay is of great importance when Rf-positive sera are analyzed. 
In the WHO report, the ClqBA gave the highest percentage of positive 
reactions and was therefore considered to be the best test for the de-
tection of circulating inmune complexes in sera of RA-patients. Our re-
sults show, however, that in this test additional complexes are formed 
in vitro. Two other tests scored high in the WHO study, viz., the mono-
clonal Rf binding inhibition radio-immunoassay and the Raji cell test. 
The former assay is directly influenced by free Rf and this renders the 
test unsuitable for RA sera. The Raji cell test has also an important 
disadvantage. It was shown that antinuclear antibodies, present in many 
RA sera, can bind to Raji cells which causes false positive reactions. 
RA-sera lacking such antibodies were, with one exception, negative in 
this assay16. The three other tests that scored positive in the WHO 
study were also based on cellular interactions and the presence of au-
to-antibodies in RA-sera against cellular components must be ruled out, 
before straightforward interpretations of such tests are possible. 
Most of the experimental data, therefore, suggest that in RA patients 
immune complexes are not present in high amounts in the circulation and 
that the ClqBA overestimates their concentration. The absence of signs 
of complement activation in RA sera is in favour of that assump-
tion17,'18. The complexes, if present, do not bind Clq in vivo to a sub-
stantial degree. It should be emphasized that our conclusions are based 
on patients who have articular manifestations of RA without systemic 
involvement. When patients with RA develop vasculitis complement levels 
become decreased19. Further studies of this subgroup of patients might 
provide more insight in the in vivo role of circulating immune com-
plexes in RA. 
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The Raji-cell test is one of the most widely used methods for the detection and quantitation of 
immune complexes. Immune complexes and not 7 S IgG bind via C3 to complement receptors 
on the cell membrane of the Raji cell. During sucrose gradient fractionation of human and 
murine systemic lupus erythematosus sera, with a high Raji cell-binding activity, we could not 
demonstrate immune complexes in these sera. Subsequent analysis showed that the major part 
of the Raji cell binding was used by 7 5 IgG with an anit-DNA specificity. Blocking experiments 
with complement-bearing aggregated IgG revealed that complement and Fc receptors were not 
involved in the binding of these anti-DNA antibodies to Raji cells. We conclude that the Raji 
cell test is not suitable for the detection and quantitation of immune complexes in sera 
containing anti-DNA antibodies. 
P. Faaber. Departments of Nephrology, Sint Radboudziekenhuis, P.O. Box 9101, 6500 HR 
Nijmegen, The Netherlands 
Systemic lupus erythematosus (SLE) is an auto­
immune disease characterized by antibodies 
against a variety of auto-antigens [11, 20]. The 
major serological marker for this disease is the 
presence of anti-ds DNA antibodies. Deposition 
of circulating DNA anti-DNA complexes is 
thought to be the mechanism responsible for the 
immunopathological manifestations. There is 
ample evidence in the literature to support this 
contention: the presence of circulating DNA 
[16, 27] and anti-DNA [27], high incidence of 
positive Raji cell binding [23], serum comple­
ment consumption [10, 18]. and deposition of 
immunoglobulins with anti-DNA specificity and 
complement components in diseased tissues, 
especially glomeruli [17, 22]. 
The Raji cell binding assay is the method most 
widely used for detection and quantification of 
immune complexes (1С) in SI.E sera [23,29,30]. 
This Burkitt lymphoma-derived human lympho-
blastoid cell line bears receptors for several com­
plement components and low-avidity Fc 
receptors. The complement receptors are pri­
marily involved in the binding of 1С [29], while 
binding to the Fc receptors has been shown to be 
negligible 128]. 
We present evidence that the Raji cell binding 
assay may not be suitable for measuring 1С in 
SLE sera. During sucrose-gradient fractionation 
of murine and human SLE sera, we have found 
that the major portion of IgG bound to the Raji 
cell did not represent 1С but 7 S IgG. Similar 
observations have been reported recently in the 
literature [4,13]. During subsequent analysis we 
were able to show that these 7 S IgG immuno­
globulins that bind to Raji cells are monomeric 
anti-DNA antibodies. 
M A T E R I A L S AND M E T H O D S 
Mice. MRl./Mp/lpr/lpr (MRL/I) mice were 
originally obtained from the Jackson Laboratory (Bar 
Harbor, Maine, USA). These mice spontaneously 
develop an auto-immunc disease very similar to 
human SLE. with formation of anti-DNA antibodies 
that increases with aging [5. 6]. BALB/c mice were 
used as controls. Both strains were kept by continuous 
brother-sister matings in our Central Animal 
Laboratory. 
Sera. Blood from MRL/I mice (aged 24 weeks) and 
BALB/c mice was obtained by bleeding from the 
retro-orbilal venous-plexus. Human sera were 
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obtained from SLE patients and from healthy volun 
tccrs After clotting for 3 h at room temperature and 
subsequent centrifugation for 5 mm at 2000 g the sera 
were ahquoted and stored at -20 o C Test samples 
were thawed only once, and heat inactivated for 
30 mm at 56°C before use 
Ann DSA antibody assays The sera for anli-DNA 
activity were analysed with the Cnthidia lucihae and 
Farr assays as described previously [1,2] Further­
more, an enzyme-linked immunosorbent assay 
(ELISA) was used to determine anti-DNA antibody 
activitv (8] Polystyrene microtitre plates (Costar 
Cambridge Mass , USA) were prccoated with 150μΙ 
0 5 mg/ml protamine chloride (Kabi AB Stockholm 
Sweden) per well during a 2-h incubation and washed 
subsequently with phosphate-buffered saline (PBS) 
DNA (100 μ\ SO^g/ml per well) was coated over 
night at room temperature Optimal concentrations of 
DNA had been determined by incubation of serial 
dilutions of DNA This resulted in increased pcrox 
idase staining until a plateau value was reached An 
excess of the optimal DNA concentration was subse 
quently used for coating, to ensure saturated binding 
to the wells The plates were washed S times with PBS 
containing 0 Ъ9с vol/vol Twecn 20 To avoid non­
specific binding the plates were subsequently coated 
for 2 h with \c'c wt/vol gelatine dissolved in PBS and 
then washed S times with PBS/0 05% vol/vol Twecn 
20 The sera were diluted in PBS containing \r/c 
wt/vol gelatine m 2-fold dilution (final volume 
100//I) After 1 h of incubation the plates were 
washed 5 times with PBS containing 0 ()59{- vol/vol 
Twecn 20 (wash buffer) Then UK) μ\ pcroxidasi con 
jugated rabbit anti-human light and hcavv chain or 
rabbit anti mouse Ig (Miles Elkhart Ind USA) 
(diluted 1 500 in PBS containing \el· wt/vol gelatine) 
were added followed by an incubation for 1 h The 
plates were washed 5 times with wash buffer and 
100//I freshlv prepared substrate solution 0 8 mg/ml 
5 aminosahcylu. acid dissolved m 50 тм phosphate 
buffer pH 6 0 containing 0 8 //l/ml 30гг vol/vol 
H О were added to each well After 30 mm the 
signal was measured at 450 nm in a I itertek* multi 
skan l o determine blank values «ells were treated in 
the same way as mentioned above but instead of 
serum l"/r wt/vol gelalim. dissolved in PBS was used 
Isokinetic \u(rou' gradient fraitioncition Sucrose 
gradient ultraccntnfugation was performed on serum 
samples from MR1/I and BAlB/c mice SLE 
patients and normal human controls Three hundred 
microhtres of scrum were layered on top of a 5 33ri 
(wt/vol) isokinetic sucrose gradient in PBS The gra 
dicnts were centnfuged at 36 (XX) rpm for 16 h at 4°C 
with an SW40 rotor m a Beekman 1.8-80 centrifuge 
The positions of IgC! IgA and IgM were determined 
with radioactive markers After fractionation of the 
gradients the bottoms of the lubes were thoroughlv 
washed with 1 fraction volume of PBS to resuspend 
the precipitated material The anli-DNA activity m 
the gradient fractions was determined with the anti 
DNA ELISA The concentrations of the various 
immunoglobulin classes were measured neph 
elometncally with the appropriate anti human Ig sera 
(Kallestad Chaska, Mich USA) or anti-mouse Ig 
sera (Meloy Springfield, Va USA) 
Preparation of DNA-anti DNA complexes in vitro 
Small-sized l4C DNA was prepared bv mixing 200/<g 
calf thymus DNA (Calbiochem La Jolla Cal , USA) 
with 12/igof |ДС Escherichia coli DNA with a specific 
activity of 40 nCi//ig (Radiochemical Centre, 
Amersham bK) This DNA mixture was digested 
with 24 U DNase I (Boehnnger Mannheim FRG) in 
PBS containing 0 1% wt/\ol BSA and 5 тм MgCl, 
After 7 mm at 4°C the reaction was quenched by an 
equal volume of ice cold PBS containing 0 2 м EDTA 
The size of the digested DNA was determined by 2% 
agarose gel electrophoresis and subsequent staining 
with cthidium bromide and autoradiography, and it 
had an average molecular weight of 120 (XX) daltons 
1С were prepared m vitro by incubating 200 μ| of an 
ami DNA positive MRL/1 scrum for 30 mm at 4°C 
with 10/jg of the »C labelled digested DNA After 
incubation this mixture was applied on top of a 5-33ri 
wt/vol isokinetic sucrose gradient 
Purification of ami DNA antibodies To obtain 
purified anti-DNA antibodies 5 ml pooled MRL/I 
serum and 5 mlofananti dsDNA positive SLE serum 
were precipitated with an equal volume of saturated 
ammonium sulphate (SAS) redissolvcd in 5 ml PBS 
and extensively dialysed against PBS An IgG fraction 
from this SAS precipitate was obtained by affinity 
chromatography on a protein A-Sepharosc 4-B col­
umn (Pharmacia Uppsala Sweden) For the isolation 
of anti DNA antibodies the protein A column cluatc 
was applied to a Cibacron blue MGA-Sepharosc 6-B 
(Pharmacia Uppsala Sweden) column [25] Before 
clution the column was washed with a buffer contain­
ing Tris HCl and 0 05 м NaCI (pH 8 0) To elute the 
bound antibodies a buffer with 0 1 м glycine and 2 M 
NaCI (pH 11 0) was used The effluent and eluate were 
dialvscd against PBS and concentrated to the original 
volume 
Raji tell auai The assay was performed with slight 
modifications according to Theofilopoulos Wilson & 
Dixon [29] with 10* Raji cells which were incubated 
for 60 mm at 37°C with 5 or 10//I serum or 50 «1 
gradient fractions with a final reaction volume of 
200//I PBS containing 0 \ci wt/vol sodium azide 
5 тм MgC I and 50 U DNase I (Boehnnger Mann 
heim FRG) After the incubation the cells were 
washed 3 times with 3 ml PBS wash buffer containing 
0 \ct wi/\ol sodium azide Immunoglobulin binding 
to Raji cells was measured either with immunofluores 
cenceorwith1 'I protein A Immunofluorescence was 
performed b\ incubating the cells for 30 mm at room 
temperature with 100/il of a 1 5() dilution in PBS of 
rabbit ami human Ig UTC (С LB Amsterdam The 
Netherlands) or sheep anti mouse Ig-FITC (Cappel 
Malvern Pa USA) I he cells were then washed 3 
times and the brightness of the fluorescence was 
graded on coded slides on a scale from 0-4+ Immuno­
globulin binding to Raji cells was measured bv adding 
12s ng ''4 protein A per 10* Raji cells Protein A was 
radiolabclled with the chloramine Τ method yielding 
a specific activity of 1 5/iCi///g 
0\A binding to Rail cells Raji cells (10*) were 
incubated for 60 mm at 37°C with 250 ng IJC-£ coli 
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DNA (Radiochemical Centre, Amcrsham, UK) and 
10/ig calf thymus DNA (Calbiochcm, La Jolla, Cal , 
USA) in 500μ\ PBS conldinmg 0 1% wt/vol BSA, 
0 01% wt/vol sodium azidc. and 5 тм MgCU After 
incubation the cells were spun down and the DNA 
activity, either bound to cells or in the supernatant was 
determined The DNA present in the supernatant was 
precipitated by adding 500 μ\ ice-cold trichloroacetic 
acid in a final concentration of 10% 
Saturation of Fc and complement receptors on Raji 
cW/t by complement-bearing aggregated immuno­
globulins Before incubation with SLE sera the Raji 
cells were incubated with complement-bearing aggre­
gated mouse (C-AMIgG) or human IgG (C-AHIgG) 
These aggregates were prepared by healing mouse 
IgG (10 mg/ml) or human IgG ( 10 mg/ml) in PBS for 
30 mm at 61°C Insoluble material formed during the 
heat aggregation was removed b) centnfugation for 
15 mm at 2000 g Serial dilutions of 75 «I of heat-
aggregated mouse IgG (10 mg/ml) or human IgG 
(10 mg/ml) in Vcronal-buffered saline containing 
0 15 тм Ca"* and 0 5 тм Mg' * (pH 7 1) were incu­
bated for 30 min at 37°C with 25 u\ normal human 
serum (final dilution 1 4) as complement source 
These mixtures were added to 106 Raji cells in 100//I 
PBS containing 0 19Ì- wt/vol BSA. 0 01% wt/vol 
sodium azide, 10 тм MgCI, and 50 U DNase I With 
,:,I-protcin A the concentration of С AMIgG or 
C-AHIgG giving maximal binding to the Raji cells was 
determined The saturating concentration of 
C-AMIgG or C-AHIgG (lOO/ig/ll)" Raji cells) was 
subsequently used for blocking complement and Fc 
receptors by preincubation of Raji cells for 60 mm at 
37°C After 3 washes with wash buffer. C-AMIgG-
premcubatcd Raji cells with human SLE sera and 
C-AHIgG-prcmcubated Raji cells were incubated 
with MRL/1 sera for 60 mm at room temperature 
After washing 3 times, the binding of normal human 
serum or human SI F sera to C-AMlgG-premcubated 
Raji cells was determined by immunofluorescence 
with 100 ¿il of a 1 50 dilution in PBS of rabbit anti-
human Ig-HTC (CLB Amsterdam. The Nether-
lands) The binding of normal mouse serum or MRL/I 
serum to C-AHIgG-premcubated Raji cells was 
scored with 100/il of a 1 50 dilution of sheep anti-
mouse IgG-FirC (Cappel, Malvern, Pa , USA) In 
the concentrations used, these FITC labelled antiscra 
did not cross-react with either mouse or human IgG 
Simultaneously with the preincubation experiments. 
the binding of the same human SI E sera and MRL/I 
sera to Raji cells was studied without preincubation of 
complement-bearing aggregated IgG After 3 final 
washes the brightness of the immunofluorescence was 
graded on coded slides by 2 different observers 
RESULTS 
Isokinetic sucrose gradient fractionation of 
human and murine SLE sera 
Five human SLE sera and 10 MRL/1 sera, 
positive in the anti-DNA ELISA (range 
Antt-DNA Antibody Binding to Raji Cells 
between 2"10 and 2"12), in the Crithtdia luciliae 
assay, and in the Farr assay, were analysed by 
isokinetic sucrose gradient fractionation The 
high Raji cell-binding activity (range between 
320 and 1800 μg equivalents aggregated 
IgG/ml) suggested the presence of circulating 
immune complexes (CIC) in these sera 
However, none of the gradients evidenced inter­
mediate-sized (between 7 S and 19 S) or large 
(>19 S) complexes The concentrations of the 
different Ig classes in the gradient fractions were 
determined nephelomctrically and revealed 
symmetric peaks at the 7 S, 9 S, and 19 S posi­
tions, for IgG, IgA, and IgM, respectively, iden­
tical to those obtained with normal human sera 
(n = 6), or with pooled normal BALB/c serum 
The lower detection limit for nephelometric 
determination of the concentration of the 
different Ig classes is below 1 ^g/ml Further­
more, all the IgG antt-DNA activity was found 
as a single peak in the 7 S region, without any 
evidence of heavy molecular weight IgG con­
taining anti-DNA activity Representative 
examples of the sucrose gradients of a human 
SLE serum and MRL/1 serum are shown in Fig 
I l o test the efficacy of the sucrose gradient 
technique in revealing DNA-anti-DNA com­
plexes, these complexes were formed in vitro by 
adding '4C-DNA to an anti-ds DNA-positive 
MRL/I serum prior to application on a sucrose 
gradient After ultracentrifugation, 40% of the 
radioactivity was recovered from the bottom of 
the gradient, whereas incubation of l4C-DNA 
with an anti-DNA negative BALB/c serum, 
under the same conditions, resulted in a position 
of the ,JC-DNA according to its size of 120.000 
daltons in the low molecular weight region (Fig 
2) 
Rajt-cell binding of isokinetic sucrose gradient 
fractions of SLE sera 
Since we could not substantiate by sucrose 
gradient fractionation the presence of circulat­
ing immune complexes in SLE sera as suggested 
by the high Raji-cell binding, we performed 
Raji-ccll assays on the sucrose gradient fractions 
of these sera Five human SLE sera and 5 MRL/1 
sera were fractionated by ultracentrifugation on 
isokinetic sucrose gradients, and each fraction 
was tested in the Raji-cell assay In all the sera 
tested, the Raji-cell binding was restricted to the 
7 S region, and no binding was observed in the 
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FIG 1 Isokinetic sucrose gradient fractionation of a human (Λ) and 
murine (B) SLF serum with a high binding activity in the Raji cell assay 
(438 and IMI ug cquiv aggregated IgG/ml respectively) The posi 
lions of IgG IgA and IgM are indicated by arrows The ordinales to the 
left of each sucrose gradient profile show the IgA and IgM concentrations 
(//g/ml) or IgG (mg/ml) The ordinate to the right of each sucrose 
gradient profile shows the absorbance at 4W nm in the anti DNA ELISA 
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Fic 2 Isokinetic gradients of l4C DNA (O—O). "C-
DNA incubated with normal mouse serum (Δ—Δ) 
and 14C-DNA incubated with an anti ds-DNA positive 
MRL/I serum (A—A) 
intermediate or high molecular weight region A 
representative experiment is shown in Fig 3 
This strongly suggests that the Raji binding of 
those sera is caused dlmost completely by the 
binding of monomenc 7 S IgG 
I о exclude the possibility that this binding was 
caused by the prior association of DNA to the 
plasma membrane of Raji cells, MC-DNA was 
added to Raji cells After an incubation of 1 h no 
radioactivity was found in pelleted Raji cells. 
and almost the total amount of added radio­
activity was recovered from the supernatant 
When DNase was added in a parallel experiment 
almost all the DNA present in the supernatant 
was cleaved, since W7c TCA precipitation of the 
supernatant yielded a precipitate containing 4% 
of the radioactive input, indicating that 96% of 
the DNA had been digested Also after DNase 
treatment no Raji cell bound activity was found 
in the pellet. indicating that small pieces of DNA 
do not stick to the membrane (Table I) All 
further experiments were done in the presence 
of DNase I 
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FIG 1 Raji cell binding of isokinetic sucrose grjdicnt fractions of a human 
SI E scrum (A) and an MRL /I serum (B) The unfractionatcd sera both 
showed a high binding in the Raji-cell assay 
Binding of purified anti-DNA antibodies to Raji 
cells 
To determine whether 7 S anti-DNA anti­
bodies in these SLE sera were responsible for 
this Raji-cell binding, anti-DNA antibodies 
were isolated by dye ligand chromatography on 
Obacron blue F3GA-Sepharose 6-B [25] The 
effluents and elualcs of a human SLE serum or 
of a pool of MRL/1 sera were tested in the 
Cnthidia lucihae assay and the anti DNA 
ELISA In the Cnthidia lucihae only the cluates 
were positive, while the effluents of both sera 
were negative In the anti-DNA ELISA the 
effluent showed a 95% reduction of the binding 
to DNA, compared to the eluate (Fig 4, upper 
panels A and B) This indicates that anti-DNA 
antibodies can be isolated by dye-ligand chro­
matography on Obacron blue F4GA The 
Obacron blue effluent and eluate of the human 
SLE serum and the MR1/1 pool were ultra-
centrifuged on sucrose gradients, and each frac­
tion was tested for its Raji-cell binding activity 
with protein A The 7 S region of the Obacron 
blue eluate of both sera containing the anti-
DN A antibodies showed considerable binding in 
contrast to the effluent, although the protein 
content of the effluent was 10-15 times higher 
than that of the eluate (Fig 4, panels С and D) 
Therefore removal of anti-DNA antibodies 
from both human and murine SLE sera led to the 
disappearance of the Raji-cell binding, while 
isolated 7 S anti-DNA antibodies showed a posi­
tive Raji-cell binding 
Binding of SLE sera to Raji cells with saturated 
complement and Fc receptors 
To test whether complement or Fc receptors 
were involved in the binding of 7 S anti-DNA 
antibodies from SLE sera to Raji cells, the latter 
were prcincubated with complement-bearing 
aggregated IgG If serial dilutions of C-AMIgG 
TABLE I Binding of IJC-DNA to Raji cells 
Cpmt 
TCA 
precipitate 
supernatant* 
17,I8I±426 
Incubation 
Raji cells+IJC DNAt 
Rajicells+^CDNA + SO 
U DNase I 
Pelleted 
Raj ι 
cells 
119+11 
67±8 1041 ±88 
* Radioactivity measured after precipitation with 
10% trichloroacetic acid 
t Total input 20,000 cpm 
íMean±SD of 3 experiments 
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Fio 4 Upper panel* Reaction pattern in ami-DNA ELISA of a human (A) and murine (B) SLE serum 
( •—A ) and the eluatc ( · — β ) and effluent (O—O) of a Cibacron blue F3G A-Sepharose 6b column of 
these sera The results are expressed as the absorption at 450 nm (A 450) Lower panels Raji-cell binding 
of the sucrose gradient fractions of the same human (C) and murine (D) Cibacron blue F3GA eluate 
( · — · ) and effluent (O—O) as shown in the upper panel The results are expressed as cpm bound x 10 ' 
or C-AHIgG were incubated with 10" Raji cells 
both aggregates showed a maximal binding at a 
concentration of I(K) /ig/lU" Raji cells (data not 
shown) Normal human sera and normal mouse 
sera did not bind to Raji cells, neither directly 
nor after preincubation with complement-bear­
ing aggregated IgG Binding of human SI F sera 
was compared with Raji cells preincubated with 
or without C-AMIgG while MRL/I sera were 
tested with Raji cells preincubated with or with­
out C-AHIgG As shown in Table II. pretreat­
ment of Raji cells with C-AHIgG prevented 
further binding of C-AMIgG and vice versa 
However, binding of human SLE sera to Raji 
cells was not influenced by the preincubation 
with C-AMIgG. and binding of MRL/I sera to 
Raj ι cells was not blocked through preincuba­
tion with C-AHIgG An example of the binding 
of a human SLE serum to Raji cells preincu­
bated with complement-bearing aggregated 
mouse IgG is shown in Fig 5 These experiments 
show that binding of SLE sera, ι e , the 7 S anti-
DNA antibodies, does not involve complement 
or the Fc receptors of these Raji cells 
48 
Anti-DNA Antibody Binding to Raji Cells 
TABLL II Influence of preincubation with complement-bearing aggregated IgG on the binding of SLE 
sera to Raji cells as measured b\ immunofluorescence 
Binding after preincubation with 
Serum 
Controls 
C-AMIgG(10()//g) 
C-AHIgG(ltK)//g) 
Normal mouse serum 
Normal human serum 
Human SLE serum 
1 
: 
3 
4 
5 
Murine SLE serum 
1 
2 
3 
4 
5 
Direct 
binding 
+ + 
+ + + 
-
-
t f 
+ + + 
+ + + 
+ + + 
+++ 
+ + + + 
+ + 
+ + + 
+ + + 
+ 
I (К)/ig complement-
bearing aggregated mouse 
IgG (C-AMIgG)* 
UK) II% complement-
bearing aggregated human 
IgG (C-AHIgG)t 
η d.t 
π d 
+ + 
+ + + 
+ + + 
+ + + 
+ + + 
η d 
n.d. 
+ + + + 
+ + 
+ + + 
+ + + 
+ 
* Immunofluorescence was performed with anti-human IgG-FITC 
t Immunofluorescence was performed with anti-mouse IgG-FITC 
t n . d =Not done. 
FIG. 5 Indirect immunofluorescence (using fluorescem-conjugated rabbit anti-
human Ig) of the plasma membrane of Raji cells after incubation with the SLE 
serum Prior to the incubation with the SLE serum the Fc and complement 
receptors were blocked with complement-bearing aggregated mouse IgG 
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DISCUSSION 
This study shows that polvclonal 7 S anti-DNA 
antibodies present in human and murine SLE 
sera can directly bind to the cell membrane of 
Raji cells A similar observation has recently 
been published bv Iron el al [31] who found 
that a murine monoclonal anti-DNA antibody 
showed a direct binding to the Raji cell mem­
brane Our study indicates that direct binding to 
Raji cells is not a unique property of a given 
monoclonal anti-DNA antibody but is also a 
feature of polyclonal human and murine anti-
DNA antibodies Complement and Fc receptors 
arc apparently not involved in this binding, since 
preincubation with complement-bearing aggre­
gated IgO did not alter the binding of SI F sera 
to Raji cells, while completely blocking the bind­
ing of complement-bearing aggregated IgG of 
the other species Furthermore, Blue Sepharosc 
effluent which did not contain anti-DNA anti­
bodies and 7 S IgG from normal sera failed to 
bind to Raji cells This observation accords with 
the finding of Tron el al [31] that the binding of 
their monoclonal anti-DNA antibody to Raji 
cells was still present if H a b ' b fragments were 
prepared It has previously been reported that 
Raji cells bind not only CIC from SI F. sera, but 
also 7 S IgG material [4, 13] Furthermore, it 
was shown by Anderson & Stillman [4] that the 
binding of 7 S IgG from SLL· sera to Raji cells 
still occurred after removal of complement and 
be receptors by pronase treatment of Raji tells 
The mechanism by which the anti-DNA anti­
bodies bind to Raji cells has not been elucidated 
However, there are a number of observations 
suggesting that phospholipids present in cell 
membrane may be the target for this binding 
Monoclonal and polyclonal anti-DNA anti­
bodies cross react with phospholipids, especially 
with cardiolipin, phosphatidic acid [19, 21, 26], 
but also, as we recently found with phosphatidyl 
glycerol (unpublished observation) Additional 
evidence that cell membrane-associated phos­
pholipids are probably involved in the binding of 
anti-DNA antibodies comes from our 
unpublished observation that purified polyclo­
nal anti DNA antibodies can also bind to a range 
of other cells such as Sp2/0-Agl4 hybndoma 
cells, RPMI 1788 cells (an Fc receptor-negative 
B-cell line), and thrombocytes It seems 
therefore that binding of anti-DNA antibodies 
to the cell membrane is not a unique property of 
Raji cells Since all experiments were done in the 
presence of DNase I, and we could demonstrate 
that l4C-DNA did not bind to Raji cells, we fee! 
justified m excluding cell membrane-associated 
DNA as the target for binding of anti-DNA 
antibodies 
Our observation, along with those reported in 
the literature [4, 13, 31], limits in our opinion the 
use of the Raji cell assay for the detection and 
quantification of CIC in sera containing anti-
DNA antibodies It also explains why the Raji 
cell test gives in general a higher incidence and 
higher levels of CIC in SLF sera than other tests 
for CIC [23] 
I here are numerous reports about the isola­
tion of DNA-anti-DNA complexes from SLE 
sera (reviewed by Theofilopoulos & Dixon [30]), 
but almost all these isolations have been done on 
serum samples m which DNA could have origi­
nated from cells lysed during the clotting With 
isokinetic sucrose gradient fractionation of S 
human and 10 murine SLL· sera with high Raji 
cell-binding activity, we found no evidence of 
CIC in these sera Other investigators also failed 
to detect DNA-anti-DNA complexes in SLE 
sera, with different methods [9, 14] Although it 
is claimed that monitoring CIC levels is useful in 
the clinical management of SLE patients [7, 12] 
there are some recent prospective studies that 
show there is no clearcut relation between clini­
cal disease activity and CIC [3,14] These obser­
vations raise the question of whether 
mechanisms other than the deposition of CIC 
may be operative in the immunopathological 
manifestation of this disease As already men­
tioned, anti-DNA antibodies show a cross-reac-
tivity with various antigens, like cardiolipin, 
phospholipids [19, 21 26], but also with gly-
cosammoglycans such as hyaluronic acid, 
chondroitin sulphate [8], and as we found 
recently, heparan sulphate (unpublished obser­
vations) The common feature of these cross-
reactive molecules is the presence of repeating 
negatively charged groups, which may be recog­
nized by anti-DNA antibodies as functional epi­
topes, since similar repeating negative groups 
are present on the DNA molecule The cross-
reactivity of anti-DNA antibodies with the gly-
cosaminoglycan heparan sulphate may be 
important with regard to the immuno-
pathogenesis of SLE-glomerulonephntis, since 
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heparan sulphate is a major constituent of the 
glomerular basement membrane and is dis-
tributed in a discrete granular pattern [15]. 
Direct binding of an t i -DNA antibodies to these 
fixed antigens, leading to in situ formation of 1С, 
rather than the deposit ion of C I C , may initiate 
the inflammation 
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Cross-reactivity of anti-DNA antibodies with proteoglycans 
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S U M M A R Y 
Ten sera of patients with systemic lupus erythematosus (SLE) were tested in an enzyme 
linked immunosorbent assay for their ability to react with glycosammoglycans consti-
tuents of proteoglycans,in relation to their anti-DNA reactivity The SLE sera reacted 
with hyaluronic acid and chondroitm sulphate and this reactivity correlated with the 
anti-DNA activity of these sera By contrast, sera obtained from patients with other 
autoimmune diseases or normal sera lacked any of these reactivities Anti-DNA 
antibodies purified by affinity chromatography with either oligo dT cellulose or Cibracon 
blue F3Ga Sepharose reacted with DNA as well as with hyaluronic acid The 
cross-reactivity of anti-DNA antibodies could be confirmed by the reaction of a mouse 
monoclonal anti-DNA antibody with DNA, hyaluronic acid, and chondroitm sulphate 
This pattern of cross-reactivities of anti-DNA antibodies suggests that several compounds 
can function as antigenic targets for these antibodies provided that their structures 
contain repeating negatively charged groups 
Keywords systemic lupus erythematosus anti-DNA antibodies proteoglycans ' 
I N T R O D U C T I O N 
In sera of patients with systemic lupus erythematosus (SLE) antibodies are present, reacting with a 
variety ofautoantigens (Hahn, 1980) However, the reaction of antibodies with dsDN A is the major 
serological marker of this disease (Deicher Holman & Kunkel. 1959, StolUr et al 1962, Arana & 
Seligmann, 1967, Kofflerera/, 1971) Recently it was demonstrated that monoclonal antibodies 
(MoAbs) directed against DNA, can cross-react with phospholipids, especiallv cardiolipin This 
was shown with MoAbs derived from the MRL/1 mouse (Lafer et al, 1981) and with MoAbs 
produced by human-human hybndomas (Shoenfeld et al, 1983) Furthermore it was shown that 
sera of^LE patients contain antibodies directed against DNA, cross-reacting to phospholipids in 
micellar form (Koike, Tomioka & Kumagai 1982) This cross-reactivity was thought to be due to 
the fact that the chemical structure of cardiolipin shows similarities to the sugar-phosphate 
backbone of nucleic acid by phosphodiester linked phosphate groups Another common feature of 
DNA and phospholipids in micellar form is the presence of repeating negative units in these 
molecules If structures with repealing negatively charged groups would form the antigenic 
determinant, that reacts with anti-DNA antibodies, other molecules fulfilling this criterium, should 
also react with anti-DNA An important group of such molecules with repeating negatively charged 
units are the proteoglycans Therefore we studied the cross-reactivity of anti-DNA antibodies with 
the glycosammoglycans hyaluronic acid and chondroitm sulphate, that are constituents of the 
proteoglycans 
Correspondence Dr Ρ Faaber, Division ofNephrology, Sint Radboud Hospital Geen Grooleplein Zuid 8, 
6525 GA Nijmegen, The Netherlands 
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MAfbRIALS AND METHODS 
Sera Blood samples were obtained from patients who fulfilled the criteria of the American 
Rheumatism Association for the classification ofSLE (Tan er α/, 1982) After clotting in glass tubes 
at room temperature for 3 h and subsequent centnfugation for 5 mm at 2,000jf, the serum samples 
were stored at —20 С All sera were heat inactivated for 30 mm at 56 С before use 
DNA and glycosammoglycam Calf thymus DNA purchased from Calbiochem, California, 
USA, was dissolved in 0 1 м phosphate buffer pH 7 4 Hyaluronic acid, obtained from Merck, 
Darmstadt, Federal Republic of Germany and chondroitin sulphate, obtained from Sigma, St 
Louis, Missouri. USA, were dissolved in 0 I M phosphate buffer, pH 7 4 
Enzyme linked immunosorbent assay (ELISA) Antibodies lo DNA or glycosaminoglycans were 
measured with a ELISA (Eaton, Schneider & Schur 1983) Polystyrene microtitre plates (Costar, 
Cambridge, Massachussetts, USA) were precoated with 150 μΐ of 0 5 mg/ml prolamine chloride 
(Kabi AB, Stockholm, Sweden) per well during a 2 h incubation and washed subsequently with 
phosphate-buffered saline (PBS) DNA (100 /il, 50 Mg, ml, per well) or glycosaminoglycans (100 μΐ, 
0 5 mg/ml, per well) were coated overnight at room temperature Optimal concentrations of the 
coated antigens had been determined by incubation of serial dilutions of these antigens This 
resulted in increased peroxidase staining until a plateau value was reached An excess of the optimal 
antigen concentration was subsequently used for coating to ensure saturated binding to the wells 
The plates were washed five times with PBS containing 0 05% vol /vol Tween 20 To avoid 
non-specific binding the plates were subsequently coated for 2 h with 2°0 wt/vol bovine serum 
albumin (BSA) dissolved in PBS and then washed five times with PBS/0 05% vol /vol Tween 20 
The sera were diluted in PBS, containing 2% wt/vol BSA, in two-fold dilution (final volume 100 μ\) 
After 1 h of incubation the plates were washed five times with PBS containing 0 1% wt/vol BSA and 
0 05% vol /vol Tween 20 (wash buffer) Then, 100 μ\ of peroxidase conjugated rabbit anti-human 
light and heavy chain (Miles Laboratories Ine , California) diluted I 500 in PBS containing 1% 
wt/vol BSA were added followed by an incubation for 1 h The plates were washed five times with 
wash buffer, and 100 μ\ freshly prepared substrate solution, 0 8 mg/ml 5 aminosalicylic acid 
dissolved in 50 т м phosphate buffer, pH 6 0, containing 0 8 μΙ/ml 30% vol /vol H2O2, were added 
to each well After 30 mm the signal was measured at 450 nm in a Titcrtek® multiskan To determine 
blank values, wells were treated in the same way as mentioned above, but instead of serum 2% 
wt/vol BSA dissolved in PBS was used When mouse MoAbs were tested, peroxidase conjugated 
rabbit anti-mouse Ig (Miles Laboratories Ine ,) was used in a dilution of 1 500 in PBS containing 
1 % wt/vol BSA In each assay a positive SLE serum and a negative normal human serum were used 
as standards The reproducibility of the assay as measured with the positive control serum was 
excellent 
Assays for anti-DNA antibodies Cnthidia luciliae and Farr assay were performed as described by 
Aarden and co-workers (Aarden, De Groot & Feltkamp, 1975, Aarden, Lakmaker & Feltkamp, 
1976) 
Purification of anti-DNA antibodies by affinity chromatography Anti-DNA antibodies were 
isolated from an SLE serum by affinity column chromatography using ohgo dT cellulose 
(Collaborative Research Ine , Waltham, Massachusetts, USA) or by Cibracon blue F3GA 
Sepharose (Pharmacia, Uppsala, Sweden) To the ohgo dT column or blue sepharose column 0 5 ml 
serum was applied The column was washed with PBS when ohgo dT was used or with 50 т м 
Tris-HCl, pH 8 0, containing 50 т м NaCI when blue Sepharose was used Bound anti-DNA 
antibodies were eluted with 20 ml PBS containing 1 м NaCI The eluted fraction and the non-bound 
protein fraction were dialysed against PBS overnight and subsequently concentrated to the original 
volume When the eluate was tested in ELISA, normal human serum (NHS) was added (final 
concentration 50% vol /vol ) to ensure a suitable protein concentration 
Radiolabellmg of human Ig Human IgG (Miles Laboratories) was radiolabelled with Na [25I 
(Amersham, UK) by the chloramine-T method (Hunter & Greenwood, 1962) Specific activity was 
2 5 MCi/^ g ,25I-IgG 
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RESULTS 
Detection of antibodies against glycoammoglycans 
Ten SLE sera containing antibodies directed against DNA as determined with the Cnthidia luciliae 
test and the Farr assay were tested in the ELISA with DNA, hyaluronic acid, or chondroitin 
sulphate as antigen. An example of the reaction pattern of an SLE serum with these antigens in the 
ELISA is shown in Fig 1. 
In all the SLE sera tested, there was a close correlation between the binding activity to DNA and 
to the glycosaminoglycans (Fig. 2), whereas normal human sera (и = 6) or a pool of normal human 
sera (л = 40) were negative with all antigens Furthermore in sera from patients with other 
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Fig. 1. Binding activity of an SLE serum with (a) DNA, (b) hyaluronic acid and (c) chondroitin sulphate as 
determined in an ELISA ( • • ) Binding activity of normal human serum ( · · ) The results are 
expressed as the absorption at 450 nm (A450) 
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Fig. 2. Correlation of the DNA binding activity of SLE sera with the binding to (a) hyaluronic acid or (b) 
chondroitin sulphate Titres of hyaluronic acid, chondroitin sulphate, and DNA, were defined as the dilution of 
each serum, thai gave 50°„ of the maximal absorption at 450 nm with the appropriate antigen 
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autoimmune diseases such as rheumatoid arthritis (η = 12), mixed connective tissues disease (1=12) 
or thyreoiditis (n= 12) both anti-glycosaminoglycans and anti-DNA activities were absent in all 
cases To exclude that the observed reactivity with hyaluronic acid was caused by a contamination 
of DNA, hyaluronic acid was treated with 10 /Jg/ml DNAase I (Boehnnger, Mannheim, Federal 
Republic of Germany) during 60 mm at 37 С in the presence of 5 т м MgCh followed by extensive 
dialysis After this treatment this antigen was used in the ELISA The results with the DNAase 
treated and untreated preparations were similar, indicating that no contaminating DNA was 
present When BSA was coated instead of DNA or the glycosaminoglycans, all sera were negative in 
the ELISA 
The reactivity of isolated ami-DNA antibodies with hyaluronic acid 
Anti-DNA antibodies were isolated from an SLE serum, which reacted strongly in the Cnthidia 
lucihae test, by oligo dT cellulose affinity chromatography The unbound fraction and the eluate 
were, after dialysis and concentration to the original volume, tested in immunofluorescence on the 
Cnthidia lucihae Only in the eluted fraction anti-DNA antibodies were detectable These fractions 
were also tested in the ELISA on DNA and hyaluronic acid and the results are given in Fig 4 The 
eluted fraction reacts with both DNA and hyaluronic acid in a dose-dependent way, whereas the 
non-bound protein fraction gives only a minimal signal When 2 μΟ human l25I-IgG was added to 
0 5 ml NHS and handled in the same way as the SLE serum on thg oligo dT column, 95% of the 
radioactivity was found in the non-bound protein fraction, which excludes that oligo dT cellulose 
binds human IgG in a non-specific way 
Anti-DNA antibodies were also isolated by blue Sepharose chromatography (Pollard & Webb, 
1982) When the non-bound protein fraction and the eluted fraction were tested with immunofluor­
escence on the Cnthidia lucihae, only in the eluted fraction anti-DNA antibodies were detected 
Both fractions were tested in the ELISA with DNA or hyaluronic acid as antigen The results given 
in Fig 4 show that antibodies, reacting with both DNA and hyaluronic acid, are only present in the 
eluate The non-specific binding of human IgG to blue Sepharose was also tested with 2 μΟ 
125I-IgG, added to 0 5 ml NHS and handled in the same way as the SLE serum 90% of the 
radioactivity was recovered in the non-bound protein fraction 
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Fig. 3. Reaction pattern of anti-DNA antibodies, isolated by oligo dT cellulose chromatography, with (a) DNA 
and (b) hyaluronic acid Original SLE serum ( · · ) eluted fraction (• •), the non-bound fraction 
(D D) and normal human serum (A A) The results are expressed as the absorption at 450 nm (A450) 
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Fig. 4. Reaction pattern of anti-DNA antibodies, isolated by Cibracon blue F3GA Sepharose, with (a) DNA 
and (b) hyaluronic acid Original SLh serum ( · · ) , eluted fraction (• •), non-bound fraction 
(O -G) and normal human serum (• A) The results are expressed as the absorption at 450 nm (A450) 
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Fig. 5. Binding activity of a mouse anti-DNA MoAb with DNA (• •). hyaluronic acid (л A), 
chondroitin sulphate (D D) A mouse MoAb of the same subclass but without anli-DNA activity was used 
as a control ( · — · ) The results are expressed as the absorption at 450 nm (A450) 
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Cross-reactiiity of monoclonal anti-DNA aniibod\ with hyaluronic acid 
Finally, to prove that the observed cross-reactivity is a property of anti-DNA antibodies, we used a 
mouse anti-DNAMoAb (provided by Τ Westgeest and L Aarden) This MoAb was obtained from 
(C57BL6 χ DBA2)Fi mice, after induction of graft versus host disease (GVHD) by injecting DBA/2 
lymphocytes In this GVHD model the mice developed a series of autoantibodies including 
anti-DNA After fusion with Sp 2/0 myeloma cells an anti-DNA MoAb that reacted positively in 
the С lucihae test was obtained This antibody was tested in ELISA with DNA, hyaluronic acid, 
chrondroilin sulphate As shown in Fig 5, this MoAb reacts with all three antigens tested 
DISCUSSION 
Our results show that in SLE sera antibodies are present, which are directed against two 
constituents of proteoglycans, ι e hyaluronic acid and chondroitin sulphate The anti-glycosa-
minoglycan activity was only found in sera with anti-DNA antibody activity and not in sera of 
patients with other autoimmune diseases, such as rheumatoid arthritis, mixed connective tissue 
disease or thyroiditis By isolating anti-DNA antibodies from SLE sera by affinity chromatography 
with ohgo dT cellulose or blue Sepharose, it could be demonstrated that it indeed were anti-DNA 
antibodies in the SLE sera that cross-reacted with hyaluronic acid Furthermore, that the observed 
cross-reactivity was a property of anti-DNA antibodies could be confirmed by using a MoAb 
directed against DNA, that also reacted with hyaluronic acid and chondroitin sulphate The fact 
that anti-DNA antibodies can bind to the sulphonated polyaromatic dye Cibracon blue F3GA 
covalently coupled to sepharose even extends the number of cross-reactive antigens This latter 
binding is broken under high salt conditions, and this indicated that the antigen-antibody 
interaction is of an ionic nature 
It was recently described, that monoclonal and polyclonal anti-DNA antibodies reacted with 
phospholipids especially with cardiohpin and phosphatidic acid (Lafer et al, 1981, Koike et al, 
1982, Shoenfeld et al, 1983) A common feature of DNA, hyaluronic acid, chondroitin sulphate, 
Cibracon blue F3GA, and the phospholipids is that they are molecules with repeating negatively 
charged groups These data together with our findings of the reactivity with proteoglycans suggest 
that anti-DNA antibodies recognize a variety of structures which contain repealing negative units 
as functional epitopes DNA is also a molecule with repeating negative phosphate groups 
Furthermore, these data could give another explanation for the diversity of autoantibodies found in 
SLE sera This apparent diversity might be generated by only a small group ofautoanlibodies which 
are reactive with a variety of antigens sharing a common feature as functional epitope The affinity 
for such antigens may vary and our preliminary data on the determination of binding to the various 
antigens suggest that the affinity to glycosaminoglycans is lower than that to DNA These 
differences certainly require further study 
From a clinical point of view the present data may help to explain some of the symptoms and 
signs of SLE Proteoglycans form an essential part of connective tissue, being present in large 
amounts, especially in the joints and skin The presence of antibodies with anti-proteoglycan 
activity may lead to inflammatory changes in these tissues, leading to arthralgia, arthritis, and skin 
rashes, which are the most common abnormalities in SLE (Tan et al, 1982) Furthermore, if our 
assumption that these antibodies are more generally directed against a variety of epitopes with 
repeating negative structures is right, then capillary basement membranes and cell membranes may 
be other targets for these antibodies We would predict that their deposition in, for instance, the 
basement membrane of the glomerulus would show not a linear but a granular pattern, because the 
charge distribution m this membrane is not homogeneous but is characterized by discrete anionic 
sites (Kanwar & Farquhar, 1979) The granular deposition of immunoglobulins found in renal 
biopsies of patients with SLE nephritis is therefore in accordance with hypothesis A similar 
explanation may hold for the granular deposits in the skin biopsies of patients with this disease This 
would imply that the damage of tissues and organs in SLE is not initiated by the deposition of 
circulating immune complexes but by the direct binding of antibodies to fixed antigenic structures in 
the target organs 
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ABSTRACT 
In 30 out of 33 human SLE sera and in 10 sera from MRL/1 mice with 
spontaneous SLE, antibodies against heparan sulphate were detected. The 
anti-heparan sulphate titers showed a significant correlation with the 
anti-DNA antibody titers. By inhibition studies it was demonstrated 
that heparan sulphate could inhibit the binding of anti-DNA antibodies 
to DNA, whereas DNA could block the binding to heparan sulphate. That 
this reaction is due to crossreactivity of anti-DNA antibodies was fur­
ther substantiated by the finding that two monoclonal anti-DNA antibo­
dies also bound to heparan sulphate. Antibodies eluted from human and 
mouse kidneys with diffuse SLE glomerulonephritis showed a similar bin­
ding to DNA and heparan sulphate when these eluted antibodies were tes­
ted in vitro. Heparan sulphate is the major glycosaminoglycan consti­
tuent of the glomerular basement membrane. Our findings suggest that 
heparan sulphate might serve as a target antigen in vivo for crossreac­
tive anti-DNA antibodies. 
INTRODUCTION 
Systemic lupus erythematosus is an autoinmune disease characterized by 
a great variety of apparently unrelated antibodies1,2, thought to be a 
consequence of polyclonal В cell activation. Recent observations mainly 
obtained with monoclonal anti-DNA antibodies, however, indicate that 
the В cell activation in SLE might be more restricted than assumed un­
til now^. It was shown that, in addition to binding to DNA, human and 
murine monoclonal anti-DNA antibodies could also react with several 
crossreactive moieties like cardiolipin and other negatively charged 
phospholipids in micellar form4,5. The moieties recognized in these 
crossreactive molecules are thought to be the phosphodiester-linked 
phosphate groups, which show similarities to the sugar-phosphate back­
bone of DNA. However, these phosphodiester-linked phosphate groups are 
not the only crossreactive moieties recognized, since monoclonal anti-
DNA antibodies can also bind to Ra]i cells6, в cells, Τ cells, erythro­
cytes7, and the cytoskeletal protein vimentin8. Moreover, we have re­
cently reported that a monoclonal anti-DNA antibody can bind to hyalu­
ronic acid and chondroitin sulphate9. These molecules do not contain 
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phosphodiester-linked phosphate groups but have other repeating nega-
tively charged units. Apparently also these structures can serve as 
crossreactive moieties for anti-DNA antibodies. The observed crossreac-
tivity is not a unique property of monoclonal anti-DNA antibodies, be-
cause also with polyclonal anti-DNA antibodies crossreactions were de-
monstrated with Raji cells10 and negatively charged molecules like car-
diolipin11, hyaluronic acid, and chondroitin sulphate9. So it seems 
that in SLE sera, a number of auto-antibody specificities can be attri-
buted to anti-DNA antibodies reacting with widely different molecules 
which all have in common that they contain repeating negatively charged 
groups. We now present evidence that monoclonal and polyclonal anti-DNA 
antibodies can bind to heparan sulphate, the major glycosaminoglycan 
constituent of the glomerular basement membrane12,13, 
MATERIALS AND METHODS 
Anti-dsDNA positive sera 
Sera containing anti-DNA antibodies were obtained from SLE patients and 
from 24 weeks old MRL/Mp/lpr/lpr (MRL/1) mice (originally obtained from 
the Jackson Laboratory, Bar Harbor, Maine, USA). These MRL/1 mice deve-
lop spontaneously an autoimmune disease very similar to human SLE, cha-
racterized by formation of anti-DNA antibodies, and diffuse prolifera-
tive glomerulonephritis14. After clotting for 3 h at room temperature 
and subsequent centrifugation for 5 min at 2,000 g, the sera were ali-
quoted and stored at -20°C. Test samples were thawed only once, and 
heat-inactivated for 30 min at 56eC before use. These sera were selec-
ted because they contained antibodies against dsDNA, as revealed by the 
dsDNA-Farr assay or Crithidiae lucilae assay. Blood from healthy volun-
teers and BALB/c mice served as normal control sera. In addition sera 
from patients with biopsy-proven primary glomerulopathy (minimal le-
sions, focal glomerulosclerosis, membranous glomerulopathy and IgA ne-
phropathy) and secondary glomerulopathy (Wegener's granulomatosis, 
Sch'ónlein-Henoch purpura and periarteritis nodosa) were used for con-
trol experiments. 
Monoclonal anti-DNA antibodies 
Monoclonal anti-DNA antibodies were kindly provided by Drs. т. West-
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geest and R. smeenk (Central Laboratory of the Red Cross Bloodtransfu-
sion Service, Amsterdam, The Netherlands) and produced as described 
previously^. 
Anti-DNA antibody assays 
Detection of anti-DNA activity was performed with the Crithidia luci-
liae and Farr assays as described by Aarden and co-workers15,16# Fur­
thermore, an enzyme linked immunosorbent assay (ELISA) was used. Poly­
styrene microtiter plates (Costar, Cambridge, Massachussetts, USA) were 
precoated with 150 μΐ of 0.5 mg/ml protamine chloride (Kabi AB, Stock­
holm, Sweden) per well during a 2 h incubation and washed subsequently 
with phosphate-buffered saline (PBS). DNA (calf thymus DNA, Sigma, 
St.Louis, MO, USA), in a concentration to ensure maximal binding (100 
μΐ, 50 yg/ml, per well) was coated overnight at room temperature. The 
plates were washed five times with PBS containing 0.05% vol./vol. Tween 
20 (wash buffer). To avoid non-specific binding, the plates were subse­
quently coated for 2 h with 1% wt/vol .gelatine dissolved in PBS and 
then washed five times with wash buffer. The sera were diluted in PBS, 
containing 1% wt/vol. gelatine, in two-fold dilution steps (final vo­
lume 100 μΐ). After 1 h of incubation the plates were washed five times 
with wash buffer. Then, 100 ul of peroxidase conjugated rabbit anti-hu­
man light and heavy chain or rabbit anti-mouse Ig (Miles, Elkhart, IN, 
USA) (diluted 1:500 in PBS containing 1% wt/vol. gelatine) were added 
and incubated for 1 h. After washing five times a second peroxidase 
labeled antibody (goat anti-rabbit IgG, Miles) was added to intensify 
the signal. The plates were washed again five times and 100 μΐ freshly 
prepared substrate solution, 0.Θ mg/ml 5'aminosalicylic acid dissolved 
in 50 mM phosphate buffer, pH 6.0, containing 0.8 μΐ/ml 30% vol./vol. 
H 2 0 2 ' w a s added to each well. After 30 min the signal was measured at 
450 nm in a Titertek multiskan. To determine blank values, wells were 
treated in the same way as mentioned above, but instead of serum 1% 
wt/vol. gelatine dissolved in PBS was used. 
ELISA for detection of antibody activity against heparan sulphate 
Heparan sulphate was purchased from Seikaguku Kogyo Ltd. (Tokyo, 
japan). Electrophoresis on cellulose acetate showed that this prepara­
tion contained only heparan sulphate and was not contaminated with 
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other glycosaminoglyeans, like chondroitin sulphate and hyaluronic 
acid, polystyrene microtiter plates (Costar Cambridge, MA, USA), pre-
coated with 150 ul of protamine chloride (0.5 mg/ml) were coated over­
night at room temperature with heparan sulphate (100 μΐ, 2.5 pg per 
well). Coating of serial dilutions of heparan sulphate revealed that 
0.4 yg per well was the minimal amount still giving a maximal ELISA 
signal.To ensure saturated binding an excess of this amount (2.5 y g per 
well) was subsequently used in all determinations. In control experi­
ments heparan sulphate was digested enzymatically with heparitinase 
(Seikaguku Kogyo Ltd, Tokyo, Japan) 1 7. After cleavage the reaction mix­
ture was dialysed overnight against PBS to remove cleaved oligosaccha­
rides. Although the heparan sulphate preparation showed no optical den­
sity at 260 nm, in a number of experiments heparan sulphate was treated 
with DNAse I (Boehringer, Mannheim, FRG) to exclude any possible conta­
mination with DNA. DNAse treatment was performed by adding an equal vo­
lume of 1.0 mg/ml DNAse I to a solution of 50 yg/ml heparan sulphate in 
PBS in the presence of 5 mM МдСІ2• This mixture was incubated during 60 
min at 370C, and subsequently dialyzed against PBS. In all experiments 
sera were also tested on wells only coated with gelatin (1% w/v) . In 
none of those, binding to gelatin was observed. If Bovine Serum Albumin 
(BSA, Sigma St. Louis, MO, USA) was used as coated antigen in the ELI­
SA, microtiter plates were coated with 150 yl 100 yg/ml BSA. The ELISA 
was performed similarly as described for heparan sulphate. 
Inhibition studies 
To demonstrate the specificity of the crossreactivity of anti-DNA an­
tibodies with heparan sulphate, inhibition experiments were performed 
with DNA and heparan sulphate. SLE sera (IF6) diluted to a concentra­
tion giving 75% of the maximal signal in the ELISA, were preincubated 
with an equal volume of 100 Ul of DNA or heparan sulphate at concentra­
tions varying from 0.25-100 ug/ml for 1 h at 37°C and subsequently for 
1 h at 0oC. DNA used for these inhibition studies was commercially ob­
tained calf thymus DNA (Sigma, St.Louis, MO, USA). Inmune complexes of 
anti-DNA antibodies with DNA or heparan sulphate were removed by cen-
trifugation at 2,000 g for 15 min at 4 0C. Supernatants of sera preincu­
bated with heparan sulphate or DNA were tested in the ELISA with DNA or 
heparan sulphate as coated antigen. 
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Inhibition studies on anti-DNA binding were also performed with Ciba­
cron Blue F3GA sepharose 6B (Pharmacia, Uppsala, Sweden), a sulphonated 
polyaromatic, polyanionic dye. SLE sera (n=3) diluted to a concentra­
tion giving 75% of the maximal ELISA-signal, were preincubated with an 
equal volume (100 μΐ) of PBS containing varying amounts (0.002-1.2 mM) 
of Cibacron Blue. The experiments were further carried out as described 
for the DNA and heparan sulphate inhibition studies. 
To exclude that DNA, heparan sulphate or Cibacron Blue inhibited anti-
DNA binding non-specifically, they were tested for their ability to in­
hibit an unrelated antigen-antibody interaction, using BSA (Sigma, 
St.Louis, MO, USA) and rabbit anti-BSA (Dako, Copenhagen, Denmark). The 
anti-BSA antiserum was diluted to a concentration giving 75% of the 
maximal ELISA signal, with BSA as coated antigen. Hundred microliters 
of diluted anti-BSA antiserum were incubated with 100 μΐ solution con­
taining the same range of concentrations of DNA, heparan sulphate or 
Cibacron Blue as used in the DNA, heparan sulphate, or cibacron Blue 
inhibition experiments of the SLE sera. The experiments were further 
carried out as described above, and the supernatants were tested in the 
ELISA with BSA as coated antigen. 
ELISA with different salt concentrations 
To test the influence of ionic strength on antibody binding, ELISA's 
with DNA or heparan sulphate were performed with different Nacl concen­
trations. After coating of the appropriate antigen under standard con­
ditions, serum dilutions of 3 different SLE sera were applied in the 
presence of increasing NaCl concentrations (range: 0.15-3 M N a d ) . Af­
ter the first incubation step, the ELISA was further carried out accor­
ding to the standard procedure. The NaCl concentrations used did not 
induce a dissociation of the coated antigens from the microtiter 
plates, since pre-incubation for 1 h at room temperature of the coated 
antigens with the used salt concentrations did not alter the subsequent 
binding of a known SLE serum. 
Elution of antibodies from kidneys with diffuse SLE nephritis 
Kidneys from 22-26 weeks old MRL/1 mice, BALB/c mice, a part of a kid­
ney from a patient with SLE glomerulonephritis and a part of a normal 
69 
human kidney were used for elution studies. These MRL/1 mice had all 
high anti-dsDNA antibody titers and diffuse proliferative glomerulone­
phritis with glomerular IgG deposits on immunofluorescence. Also the 
patient with a classical SLE and a biopsy-proven diffuse proliferative 
glomerulonephritis had high anti-dsDNA antibody titers. The kidneys 
used for control experiments showed no abnormalities on light microsco­
py and immunofluorescence. The kidney tissue was homogenized and washed 
extensively in 0.01 M phosphate buffered saline until no absorbance at 
280 rm was found in the wash solution. The tissue homogenate was resus-
pended in 0.1 M sodium acetate buffer (pH 7.0) containing 10 mM cal-
ciumchloride and 5 mM magnesiumchloride. To 15 g of tissue homogenate 1 
mg DNAse I and 10 units heparitinase were added. This mixture was incu­
bated for 4 h at 37"C and 16 h at 40C under constant stirring. The tis­
sue homogenate was spun down in a SW34 rotor at 6,000 rpm for 15 min at 
4eC. The pellet was resuspended in 30 ml 0.02 M citrate buffer pH 2.85, 
and under constant stirring incubated for 2 h at room temperature. Af­
ter centrifugation (15 min, at 4eC in a SW34 rotor, 6,000 rpm) the elu­
tion procedure was repeated once. The supernatant was brought back im­
mediately to pH 7 with Tris-buffer. The precipitate formed during pH 
titration was removed by centrifugation. The eluate was dialyzed over­
night against PBS, and subsequently concentrated with an Amicon УМ 50 
filter to a volume of 5 ml. The IgG concent was determined nephelome-
trically. The control eluates of the BALB/c kidneys and the normal hu­
man kidney were concentrated to the same IgG concentrations as the 
MRL/1 eluate and the human SLE eluate respectively. Additionally, an 
eluate of rat kidneys with experimentally induced Heymann's nephritis 
was used for control experiments. This eluate (IgG concentration 160 
pg/ml) was a generous gift fron Dr. E. de Heer (Dept. of Nephrology, 
Leyden State University, Leyden, The Netherlands) and obtained as pu­
blished before1**. 
RESULTS 
Reactivity of human and murine SLE sera with heparan sulphate 
Thirty out of 33 human SLE sera (positive in the Farr assay, the Cri-
thidia luciliae test and DNA-ELISA) showed a positive binding with he­
paran sulphate as tested in the ELISA. A representative serum is shown 
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Fig. 1. Binding activity in ELISA to DNA and heparan sulphate of a hu­
man SLE serum (·-·) and a pool of normal human serum (•-•). The 
results are expressed as the absorption at 450 nm (A450). 
in fig. 1. As can be seen from fig.2, we found a clear correlation 
(r=0.73) between the anti-DNA titer and the anti-heparan sulphate titer 
in these 33 SLE sera. The mean anti-DNA titer of these sera was appro­
ximately 3 times higher (mean log 2 titer ± SD; 8.7 ± 1.9) than the 
mean anti-heparan sulphate titer (7.2 ± 2.5). Three out of 33 SLE sera 
showed no binding activity for heparan sulphate although an evident 
binding to DNA was present. A significant correlation (r=0.77) was also 
found between the anti-DNA titer and anti-heparan sulphate titer in 10 
MRL/1 mouse sera, which were all positive in the Farr assay and Crithi-
dia luciliae test (data not shown). The binding activities of a serum 
pool from 40 healthy volunteers and of 8 sera from patients with rheu­
matoid arthritis were negative in the DNA- as well as in the heparan 
sulphate-ELISA. Also in sera from normal BALB/c mice (n=40) anti-DNA as 
well as anti-heparan sulphate activity was never detected. The observed 
binding of SLE sera to heparan sulphate cannot be attributed to the 
higher IgG concentration of these sera since the mean IgG concentration 
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of these SLE sera (22 ± 9 mg/ml; range 7.0-41 mg/ml) was only two to 
four times higher than the control sera (10 mg/ml) while the average 
binding to heparan sulphate of these SLE sera was approximately 100 
times higher than of the control sera. 
Titer ant i-DNA 
-13 
Titer anti-heparan sulphate 
Fig. 2. Correlation between the anti-DNA titer and the anti-heparan 
sulphate titer of 33 human SLE sera (r=0.73; p<0.001). The an-
tibody titer for DNA or heparan sulphate is expressed as the 
dilution which gives an A450 signal of 0.5 in the ELISA. 
Furthermore, there was no correlation between the anti-heparan sulphate 
titer and the IgG concentration. Sera from patients with primary glome-
rulopathy (n=12) and patients with glomerulopathy secondary to systemic 
diseases other than SLE (n=21), were also tested for their reactivity 
in the DNA and heparan sulphate ELISA (table I ) . None of these sera 
showed a positive binding to either of these antigens. To exclude any 
DNA contamination of the heparan sulphate preparation, ten human SLE 
sera were tested with heparan sulphate pretreated with DNAse I. We ob-
served no difference in binding activity of these sera with heparan 
sulphate whether it was pretreated with DNAse I or not. However, treat-
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ment of heparan sulphate with hepantinase abolished the binding acti­
vity of these SLE sera (n=10) (data not shown). 
Table I. Reactivity with DNA and heparan sulphate of sera from pa­
tients with primary or secondary glomerulopathy 
Number 
tested 
DNA Heparan 
Sulphate 
Primary glomerulopathy: 
Minimal lesions 
Membranous glomerulopathy 
Focal glomerulosclerosis 
IgA-nephropathy 
Secondary glomerulopathy : 
Wegener's granulomatosis 
Schonlein-Henoch purpura 
Periarteritis-nodosa 
3 
4 
2 
3 
12 
5 
4 
neg. 
neg. 
neg. 
neg 
neg. 
neg. 
neg. 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
Inhibition studies 
To demonstrate that the binding to heparan sulphate was due to cross-
reactivity of anti-DNA antibodies, blocking experiments with DNA and 
heparan sulphate were performed. Inhibition studies were done with five 
human SLE sera and with a serum pool of MRL/1 mice (n=40). These sera 
had a comparable binding activity to DNA as to heparan sulphate. The 
maximal inhibition observed with DNA or heparan sulphate for the diffe­
rent sera on subsequent binding to DNA is shown in table II. As can be 
seen the range of inhibition of DNA to subsequent binding to DNA varied 
from 28 to 98% for the various sera. Heparan sulphate did also inhibit 
binding to DNA, although for some sera (#3 and #5) the inhibition was 
lower than with DNA. The maximal inhibition obtained with DNA on subse­
quent heparan sulphate binding varied from 60 to 100 percent and was 
comparable to the inhibition of heparan sulphate on subsequent heparan 
sulphate binding (table II). If heparan sulphate was digested with he­
pantinase the inhibitory effect of heparan sulphate was completely 
abolished in all four SLE sera tested. Fig. 3 depicts in detail the in­
hibition curve observed for serum #1, showing that heparan sulphate and 
DNA inhibit in a similar, dose dependent way the binding of DNA (fig. 
ЗА) or heparan sulphate (fig. 3B). Furthermore, it shows (fig. ЗА) that 
digestion of heparan sulphate with heparitinase leads to a complete 
loss of the inhibitory effect of heparan sulphate. 
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Table II. Percentage of maximal inhibition by DNA or heparan sulphate 
on subsequent DNA and heparan sulphate binding of a serum 
dilution giving 75% of the maximal ELISA signal 
Coated Antigen: DNA 
Fluid Phase Inhibitor*: DNA 
Heparan sulphate 
98 
92 
во 
28 
59 
Heparan 
sulphate 
90 
94 
36 
23 
45 
DNA 
88 
99 
70 
60 
71 
Heparan 
sulphate 
76 
95 
82 
80 
86 
HS # 1 
HS # 2 
HS # 3 
HS # 4 
HS # 5 
MRL/1 serumpool 80 80 90 74 
Amount of inhibitor per well 10 \iq 
HS = human SLE serum 
% inhibition 
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Fig. 3. Inhibition of the binding of a human SLE serum preincubated 
with DNA (·-·) or heparan sulphate (•-•), or heparitinase 
treated heparan sulphate (Α-A) on subsequent binding to DNA 
(fig. ЗА) or heparan sulphate (fig. 3B) . The results are ex­
pressed as % inhibition calculated as: 
EÀ450 in the presence of inhibitor-! χ ιοο A450 in the absence of inhibitor I L  
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Fig. 4. Representative experiment on inhibition with Cibacron Blue on 
anti-DNA binding of a human SLE serum, inhibition was calculat­
ed as in fig. 3. 
The binding of anti-DNA antibodies to DNA could not only be inhibited 
by heparan sulphate, but also by another, unrelated, highly polyanionic 
structure: Cibacron Blue. In the three SLE sera tested we found that 
Cibacron Blue exerted the same inhibitory effect on DNA binding as he­
paran sulphate. Fig. 4 depicts the dose dependent inhibition with Ciba­
cron Blue for one of the sera analyzed. 
To show that DNA, heparan sulphate, and cibacron Blue did not inhibit 
non-specifically the binding of anti-DNA to DNA we performed similar 
inhibition experiments with these reagents in an unrelated antigen-an­
tibody system e.g. BSA-anti BSA. Preincubation of anti-BSA antiserum 
with DNA, heparan sulphate or Cibacron Blue under the same conditions 
as used in the anti-DNA inhibition studies, did not inhibit at any con­
centration the subsequent binding of anti-BSA to BSA in the ELISA (data 
not shown). 
\ 
λ 
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Influence of the ionic strength on the binding of anti-DNA to DNA and 
heparan sulphate 
To test the influence of ionic strength on the binding of anti-DNA to 
DNA and heparan sulphate ELISA's were performed in the presence of in­
creasing concentrations of NaCl. Fig.5, depicting results obtained with 
one of the tested sera, shows that increase of the ionic strength re­
sulted in a similar dose-dependent decrease of the binding to both DNA 
and heparan sulphate. The binding to heparan sulphate and DNA in two 
other sera tested was also equally sensitive to increasing salt concen­
trations although there were differences in sensitivity between the se­
ra. As already mentioned this decrease in binding is not due to an en­
hanced dissociation of the coated antigens under the higher salt condi­
tions used in the tests. 
Binding of monoclonal anti-DNA antibodies to heparan sulphate 
To substantiate further that antibodies with an anti-DNA specificity 
can bind to heparan sulphate, two monospecific murine monoclonal anti-
DNA antibodies were tested for their binding activity to heparan sul­
phate. Both monoclonal antibodies showed a similar reaction pattern in 
the ELISA with either DNA or heparan sulphate. The binding activity of 
one monoclonal anti-DNA antibody is shown in fig.6. 
Binding to heparan sulphate of antibodies eluted from SLE kidneys 
To investigate whether anti-DNA antibodies deposited in vivo in SLE-
glomerulonephritis could bind to heparan sulphate, antibodies were 
eluted from MRL/1 kidneys and from a kidney of an SLE patient with a 
diffuse proliferative glomerulonephritis. For control experiments kid­
neys from normal BALB/c mice and a part of a normal human kidney were 
eluted. The MRL/1 and human SLE eluate contained 128 and 263 )ig IgG/ml 
respectively and were positive in the Crithidia luciliae test, in con­
trast to the eluate of normal BALB/c kidneys (IgG content: 4 yg/ml) or 
normal human kidney (IgG content 5 yg/ml). то exclude that the higher 
IgG content of the SLE eluates caused a non-specific binding, both con­
trol (human and murine) eluates were concentrated to the same IgG con­
tent as the SLE eluates. As shown in fig. 7 the MRL/1 and human SLE 
kidney eluate showed a comparable binding in the DNA and heparan sul-
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Fig.5 influence of increasing Fig. 6. Reaction pattern of a mouse 
ionic strength on the 
binding of a human SLE 
serum to DNA (·-·) and 
to heparan sulphate 
(•-D) . The results are 
expressed as the absorp­
tion at 450 nm (A450). 
monoclonal antibody with DNA 
(·-·) or heparan sulphate 
(•-•). In control experi­
ments a mouse anti-human Τ 
cell monoclonal with the 
same subclass was tested for 
its reactivity to DNA (o-o) 
or heparan sulphate (n-D). 
The results are expressed as 
the absorption at 450 nm 
(A450). 
phate-ELISA, while the concentrated BALB/c and normal human eluates 
were negative for both antigens. The binding activity of IgG in the hu­
man and murine SLE eluates to heparan sulphate could be inhibited by 
DNA, indicating that both antigens were recognized by the same antibody 
specificity. Although we cannot exclude unequivocally that the entrap­
ment of serum IgG in the kidney eluates contributed to the anti-DNA and 
anti-heparan sulphate binding activity of the eluates, this seems very 
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Dilution 
Fig. 7. Reaction patterns of IgG eluted from a human SLE kidney with 
DNA (*-*) and heparan sulphate (•-•) and IgG eluted from MRL/1 
kidneys with DNA (·-·) and heparan sulphate im-m), Control ex­
periments were performed with IgG eluted from BALB/c kidneys, 
normal human kidney, and rat kidneys with experimental Hey-
mann's nephritis on DNA (o-o) and heparan sulphate (Π-D). The 
results are expressed as the absorption at 450 nm (A450). 
unlikely since the specific anti-DNA activity per \ig IgG eluted from 
the human and murine SLE kidneys was respectively 4 and 7 times higher 
than the anti-DNA activity per μ g serum IgG. 
Since elution studies of normal kidneys cannot be regarded as optimal 
control experiments we analysed in addition the anti-DNA and heparan 
sulphate binding activity of a kidney eluate of an experimentally in­
duced Heymann's glomerulonephritis in the rat. This eluate (160 μ g 
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IgG/ml) did not show any binding activity in the anti-DNA and anti-he-
paran sulphate ELISA. 
DISCUSSION 
This study shows that in 90% of human SLE sera (selected for the pre-
sence of anti-dsDNA autoantibodies) and in all the murine SLE sera an-
tibodies are present directed towards heparan sulphate. In these sera 
the anti-heparan sulphate titer was positively correlated with the an-
ti-DNA titer (r=0.73). Binding to heparan sulphate was not found with 
sera from healthy volunteers, patients with rheumatoid arthritis or pa-
tients with primary or secondary glomerulopathy due to systemic disea-
ses other than SLE. 
Inhibition studies revealed that heparan sulphate could block the bin-
ding to DNA and that DNA could inhibit the binding to heparan sulphate, 
indicating crossreactive recognition of heparan sulphate by anti-DNA 
antibodies. The specificity of the anti-DNA binding to heparan sulphate 
was demonstrated in several ways. Firstly, we could exclude DNA conta-
mination of the heparan sulphate preparation, since the optical density 
of the heparan sulphate preparation at 260 nm was zero and DNAse I 
treatment of heparan sulphate did not influence the subsequent binding 
of anti-DNA antibodies. Secondly, treatment of heparan sulphate with 
heparitinase not only abolished the subsequent binding of anti-DNA an-
tibodies to digested heparan sulphate, but also the inhibitory effect 
of heparan sulphate on subsequent binding to DNA. Thirdly, heparan sul-
phate (as well as DNA or Cibacron Blue) did not inhibit antibody bin-
ding in an unrelated antigen-antibody system (BSA-anti BSA). 
That the binding of anti-DNA to heparan sulphate is due to a non-speci-
fic charge interaction seems unlikely for different reasons. We did not 
observe any binding of non-SLE sera to heparan sulphate. If serum IgG 
would bind by a non-specific charge interaction to heparan sulphate, 
one would expect that also some of these sera would show binding to he-
paran sulphate and that there existed a correlation between serum IgG 
concentration and heparan sulphate titer. Finally, the strongest argu-
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ment can be derived from the studies showing the influence of ionic 
strength on antibody binding to DNA and heparan sulphate. Previous stu-
dies from Aarden and coworkers have demonstrated that non-specific bin-
ding to DNA does not occur if the ionic strength exceeds 0.2 M NaCl, 
and that the binding of anti-DNA to DNA was of electrostatic na-
ture16, 21, since anti-DNA binding to DNA decreased with increasing 
ionic strength. We observed that the binding to heparan sulphate was 
equally influenced by increasing ionic strength as the binding to DNA/ 
in each serum tested, although there existed differences in sensitivity 
for ionic strength between the different sera. Therefore, the binding 
of anti-DNA to heparan sulphate seems to be governed by the same elec-
trostatic forces as the antigen-antibody interaction of DNA and anti-
DNA. 
Although our inhibition studies have revealed the crossreactive recog-
nition of heparan sulphate by anti-DNA antibodies, they also showed 
that in certain sera, the inhibition of DNA binding obtained with hepa-
ran sulphate was less than that found with DNA while the inhibition of 
DNA and heparan sulphate on heparan sulphate were comparable. This in-
dicates that these sera contain additional non-crossreactive anti-DNA 
antibodies. Besides the amount of crossreactive anti-DNA antibodies, as 
revealed by heparan sulphate inhibition of anti-DNA binding, also the 
avidity of the anti-DNA antibodies seems to be important since in cer-
tain sera, DNA in the fluid phase was not able to prevent completely 
subsequent binding to solid phase DNA. 
However, in certain sera the concentrations necessary for 50% inhibi-
tion of binding to both antigens were similar, indicating that depen-
dent on the amount and avidity of the crossreactive anti-DNA antibodies 
heparan sulphate can serve under these circumstances equally well as 
antigenic target for anti-DNA antibodies as DNA. That anti-DNA antibo-
dies could bind to heparan sulphate was unequivocally confirmed with 
the two monoclonal anti-DNA antibodies, since these monospecific anti-
bodies bound equally well to heparan sulphate as to DNA. 
The crossreactive recognition of anti-DNA antibodies is not restricted 
to heparan sulphate. We have previously reported that other polyanionic 
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molecules such as chondroitin sulphate and hyaluronic acid, can also 
bind to anti-DNA antibodies9. In addition, we have shown in this study 
that another unrelated highly anionic molecule, Cibacron Blue, could 
inhibit anti-DNA binding to DNA to the same extent as heparan sulpha-
te . This observation is in line with earlier reports in which Cibacron 
Blue was used to purify anti-DNA antibodies^9, or to inhibit anti-DNA 
binding to DNA in the Farr assay20, 
Primarily based on studies with monoclonal antibodies22,23, anti-DNA 
antibodies can be divided in antibodies reactive with DNA nucleotides 
or nucleotides sequences and those reactive with the sugar phosphate 
backbone of DNA. The latter are thought to be responsible for cross-
reactive binding of anti-DNA antibodies to several molecules3. There 
exists, however, still some controversy about the composition and cha-
racteristics of the crossreactive targets, stollar, Schwartz and cowor-
kers have proposed that the crossreactive moieties are phosphodiester 
linked phosphate groups. However, we propose, based on our previous ex-
periments with hyaluronic acid and chondroitin sulphate9, the reported 
reactivity of anti-DNA antibodies with Cibacron Blue19,20 and the pre-
sent results with heparan sulphate and cibacron Blue that molecules 
with repeating anionic sites also can serve as crossreactive antigenic 
targets for anti-DNA antibodies. 
The crossreactivity of anti-DNA antibodies with the glycosaminoglycan 
heparan sulphate may play an important role in the immunopathogenesis 
of SLE glomerulonephritis. Heparan sulphate is the major glycosamino-
glycan constituent of the glomerular basement membrane (GBM) and it is 
distributed in a discrete granular pattern13, in this regard it is 
worth noting that in patients with diffuse SLE glomerulonephritis depo-
sitions of IgG in the glomerular capillary wall also show a granular 
pattern in immunofluorescence. Heparan sulphate has a major role in the 
maintenance of the charge selective barrier of the GBM24. Furthermore, 
recent experiments have indicated that heparan sulphate may also have 
an important function in the integrity of the size-selective barrier of 
the GBM2-»,26. Reduction or neutralization of heparan sulphate in the 
GBM leads to proteinuria in experimental animals24,27· Clinically, a 
reduction of heparan sulphate-associated polyanionic sites has been 
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held responsible for proteinuria in congenital nephrotic syndrome28. In 
addition to their function in glomerular permeability, there is now al-
so evidence that anionic sites within the glomerulus may determine the 
intra-glomerular handling of circulating antigens, antibodies and im-
mune complexes2^. Therefore binding of anti-DNA antibodies to the hepa-
ran sulphate associated polyanionic sites in the GBM might be an impor-
tant event in SLE nephritis either by interference with physiological 
functions and/or by triggering inflammatory reactions locally. This hy-
pothesis implies that glomerulonephritis in SLE patients might occur by 
a direct binding of anti-DNA antibodies to heparan sulphate. Our fin-
ding that anti-DNA antibodies eluted from kidneys with diffuse SLE glo-
merulonephritis can bind to heparan sulphate in vitro supports this hy-
pothesis. Studies are now in progress to see whether anti-heparan sul-
phate activity in the serum of SLE patients is correlated with the pre-
sence of glomerulonephritis. 
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INTRODUCTION 
Systemic lupus erythematosus is an autoimmune disease characterized by the presence of a great 
variety of apparently unrelated antibodies''^ , thought to be a consequence of polyclonal В 
cell activation. However, in recent years a new pictare is emerging fron observations initial­
ly obtained with murine and human monoclonal anti-DNA antibodies, indicating that the Б cell 
activation in SLE might be more restricted than has been assumed until now. It was shown that 
some of these monoclonal antibodies, besides binding to DNA, could react with several cross-
reactive epitopes other than DMA. Subsequently, it was found that also polyclonal anti-DNA 
antibodies showed a similar crossreactive binding pattern. Here we will report our own studies 
and the data from the littérature concerning the structures that are recognized by anti-DNA 
antibodies (Table I) and the possible implications of these findings for the inmjnopathology 
of SLE. 
Table I. Crossreactions of anti-DNA autoantibodies 
Structure Reference number 
11,own observations 
Phospholipids 
- cardiolipin 
- phosphatidic acid 
- phosphatidyl glycerol 
Glycosarainoglycans 
- hyaluronic acid 
- chondroitin sulphate 
- heparan sulphate 
Polyanionic structures 
- Cibacron blue F3CA sepharose 
- Dextran sulphate 
11,12,15,own observations 
3,14 
16 
Cells 
- Raji cell 
- Sp 2/0 myeloma 
- RPMI 17ΘΘ cell-line 
- Τ cells 
- В cells 
- erythrocytes 
5,9,19 
; own observations 
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ALTOAMIBODILS IN DISEASb 
Based on these findings it seems that anti-DNA antibodies can be divided into specificities 
primarily directed against nucleotides or specific nucleotide sequences of DNA that do not 
crossreact, and in specificities that are directed against the backbone of DNA. These latter 
snecificities show also crossreactive binding to many other structures. The results obtained 
with the various crossreactive moietieb will be discussed respectively. 
EVIDENCE Ol· CROSSREACTIVITY 
7
'л Polyclonal anti-DNA antibodies from 21 out of 22 human SLE sera did bind to RNA These 
sera showed in the ELISA a similar reaction to RNA as to DNA, while the binding to RNA could 
be blocked by DNA and vice versa. Also monoclonal anti-DNA antibodies (9 out of 15) showed the 
чате cross reactivity. These findings are in accordance with crossreactions to synthetic RNA**. 
~hcspholipz'ls. Human and murine monoclonal anti-DNA antibodies can bind to cardiolipin and 
other phospholipids. This crossreactivity is restricted to negatively charged phospholipids, 
while those with a positive NH3 + group (phosphatidylethanol amine, phosphatidyl choline and 
phosphatidyl serine) do not bind. The crossreactivity is caused by phosphodiester linked pnos-
phate groups, which mimic the sugar-phosphate backbone of DNA. For the other phospholipids, 
that do not contain these phosphodiester linked phosphate groups, one has to assume that, 
through the prebentation of the phospholipids in micellar form, structures are created which 
minie the geometry of the DNA backbone. However, the positively charged phospholipids, present­
ed in the «sane micellar form, do not show this crossreactivity, indicating that Che charge of 
these ohospholipids play an important role in the crossreactivity of anti-DNA antibodies. With 
polyclonal anti-DNA antibodies from SLE patients we found in 10 out of 11 sera binding of anti-
DNA to cardiolipin, phosphatidic acid, and phosphatidyl glycerol. These observations are in 
agreement with the findings of Koike et al^ . This crossreactivity may explain the frequently 
observed false-oositivc serologicdl test for syphilis in patients with SLE^i. Furthermore, 
this anti-cardiolipin activity nay be responsible for the lupus anti-coagulant which sometimes 
is found in SIEQ. 
J\< ••сз^ггг^ ιlj-*a>b0. That not only molecules with repeating negatively charged phosphate groups 
could serve as a crossreactive epitope was demonstrated by our finding that polyclonal and mo­
noclonal anti-DNA antibodies could also bind to hyaluronic acid, chondroitin sulphate^ and he-
parar sulphare**. A common feature of these molecules is that they contain repeating negatively 
c
v
arged groups, mainly sulphate groups. Therefore not only phosphodiester Linked phosphate 
groups but also polyanionic molecules show binding to anti-DNA antibodies. Using heparan sul-
pnate (HS) аь coated antigen in an ELISA system we found that 60 out of 63 anti-DNA positive 
human SLE sera, and 10 out of 10 MRL/1 sera gave a similar binding to HS as to DNA. The bin­
ding to HS could be blocked by equal amounts of DNA and vice versa. Antibodies eluted from mu­
rine and human SLE Kidneys gave a similar binding to HS as to DNA, whereas the binding to HS 
could again be blocked by DNA. In addition 16 out- of 30 monoclonal anti-DNA antibodies cross-
reacted with HS. All these monoclonal antibodies were positive in the anti-DNA ELISA, negative 
in the Farr assay and 50% of them were positive in the Crithidia luciliae assay. There was, 
however, no correlation between positivity in the Crithidia assay and positive crossreaction 
with HS We could therefore, not confinn that only low-avidity anti-DNA antibodies crossreact-
ed with HS, as has been suggested for the crossreactive binding to dextran sulphate^. 
^ai'jaKtrni ' r t r ^ t tres. The recognition of molecules with repeating negatively charged groups 
by anti-DNA antibodies was further substantiated by the finding that the anionic sulphonated 
polyaromatic dye Cioacron blue F3GA coupled to Sepharose C14B (CB) could be used to purify 
anti-DNA antibodies from SLE sera* . Inhibition studies with CB to DNA showed, similar to our 
observationb with HS, that binding to CB occurred at the antigen binding site-*. A monoclonal 
anti-DNA antibody directed against the DNA phosphate backbone bound to CB, whereas a monoclo­
nal anti-DNA antibody primarily directed against bases did not. It seems that the sulphonated 
polyaroraatic groups on CB with their polyanionic nature can serve as antigenic target for both 
polyclonal and monoclonal anti-DNA antibodies. 
Culi я it*f ice s truci AVO s. In several studies the binding of monoclonal and polyclonal anti-DNA 
antibodies to surfaces of different cells like Raji-cells, Τ and В cells and erythrocytes was 
reported ' »I 0» 1 9, we were able to demonstrate that in human and murine SLE sera with high 
На]і cell binding activity no inmune complexes were detectable by sucrose gradient fractiona­
tion and that the high Raji-cell binding activity in these sera was caused by the direct bin­
ding of monomeric 7S anti-DNA to the cell membrane without involvement of Fc and C3 receptors^. 
This observation is in line with the finding of Tron et al. that a monoclonal anti-DNA antibo­
dy as well as its F(ab)2 fragment bind to Raji cells*". Further analysis revealed that five 
membrane bound proteins were responsible for the binding activity with this monoclonal anti-
DNA antibody'-*'*^. However, it has been reported that the binding of 7S IgG from SLE sera to 
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CROSS ИЬАСТІ ІТЧ OF AM I DNA ЛМ ІВОГШ S 
Ra^i cells still occurred after removal of membrane bound proteins by pronase treatment^ At 
this moment it is therefore not clear which antiqen is the target for this anti-DNA autoarti-
body binding, but phospholipids in the membrane are a possibility From these observationb it 
is clear that, due to the crossreactivity of anti-DNA antibody, the Raji cell assay is not 
suitable for the detection of circulating immune complexes in SLE sora This crossreactive 
binding of anti-DNA antibodies to cell surfaces is not restricted to Raji-cells since we also 
found binding to Sp 2/0 nybridoma cells, RPMI 17ΘΘ cells (an Fc receptor negative B-cell li ie) 
(unpublished observations), and Jacob et al. found binding to Τ and В celis, er\throcytes and 
thrombocytes^ 
POSSIBLE CONSEQUENCES OF CROSSREACTIVITY 
At this moment a large number of crossreactive antigens are recoqnized b\. тіопосіопаі and po­
lyclonal anti-DNA antibodies. Based on the crossreactions with phobpholipids it ι as been s ig-
gested that phosphodiester linked phosphate groups are the crossreactive noieties^-'^ How­
ever, our observations with glycosaminoqlycans'* »6
 a n
d those reported with Cibacror blue·1' , 
and dextran sulphate , which are molecules that do not contain phosphodiester linked phos­
phate groups, have indicated that also these molecules can serve as a crossreactive entope 
for anti-DNA antibodies. The common feature of all these molecules is tv at *rej ^ctdin геэеа-
ting negatively charged дгоирь, which are to our opinion tne taraet for cross-reautive anti-
DNA antibodies This is further substantiated bv our findirg that the ьачю nonoiio al anti-DNA 
antibody could bind to various crossreactive antiaens Thib сгоь^reactivit> o f anti-DNA also 
sheds a new light on the diverbity of serological aLnormalities in SLE, which та} Ы generated 
by a restricted number of autoantibodies reacting witn a vanet/ of antigens si aring a comron 
feature as epitope It is therefore possible that a number o* aL-o-antiboa Lpec^ + i'-i^ -ies ap­
parently present in SLE sera are in fact causea by anti-DNA antibodies. This -na^  indicate that 
the В cell hyperreactivity in SLE is more restricted trian assuned until now 
These crossreactions might also have implications for *-he inLTunooatholoaical eve'-tb tiat 
are operative in SLE Most tissue lesions in SI F are co^siderea to ЬР tie .^J beiaen^e of depo­
sitions of DNA anti-DNA immune complexes However, the presence oe UNA is \orv dircJ.>.ult to 
prove, because when using serum sampleb it is known that DNA is released from Ыооа сеііь du­
ring clotting. The same holds true for isolation from tissues The proceduics jseJ ^or isola­
tion do not guarantee that cells remain intact Furthemore dsDNA is not imrunoie^ с after 
deliberate iraiounization , and if DNA is in]ected irto ar lirais producirg a it^-DNA autoantibo­
dies it is not localized in the diseased tissues . Also tne recent finding that anti-DNA arti-
bodies can cause positive Raji-cell binding, thereby erroneously suggesting th" oresence o* 
immune complexes, indicates that probably the role of immune complexes in tne oatnocienesis o* 
SLE has been overestimated. The observed cross-reactivity pc-.rts to anotner innunopathological 
mechanism Hyaluronic acid and chondroitin sulphate are present m fairly larqe quant^t-eb in 
connective tissue m joints and skin Crossreactive binding of anti-DNA autoantibodies na^ 
initiate inflammatory changes, leading to arthralgias, arthritis ana SKIT lesions Heparan sul­
phate (HS) is the major glycosaminoglycan of the glomerular oasemert irenbra-e \GBM , d^btnti-
ted in a discrete granular pattern, and it has a major role ir the maintenance о* the charge 
selective barrier of the GBM, and probably also in the sire-selective barrier of the GBM Pro­
teinuria occurs when the amount of HS is decreased, neutralized by cationn. moleculcj or af'-er 
binding of antibody to HS Therefore direct binding of anti-DNA antibodies to HS ir t e GBM, 
rather than depositions of DNA anti-DNA antibodies, may lead to proteinuria and triggering oe 
an inflammatory reaction resulting in glomerulonephritis rurther in vivo studies a'-e reejed 
to prove this hypothesis 
Finally, this cross-reactivity opens the possibility that the triggering antincn in SLE 
could be a cross-reactive molecule, rather than DNA itself, which COUIJ also exnlai^ M e low 
immunogemcity of dsDNA itself 
These studies were supported by a grant from the Dutch League agairst Rneumatisr. 
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CHAPTER θ 
DISCUSSION 

DISCUSSION 
In the last two decades much attention has been paid to the role of 
circulating immune complexes (CIC) as pathogenic agents in many diseas­
es, especially in systemic autoimmune diseases such as rheumatoid ar­
thritis (RA) and systemic lupus erythematosus (SLE) (1,2). More than 
twenty assays have been developed to detect inmune complexes (1С) in 
serum and other biological fluids. These tests are based on different 
properties of 1С, either physicochemical or biological (interaction 
with complement components, rheumatoid factors, or cell surface recep­
tors) . When using these tests in the diagnosis of autoimmune diseases 
it is important to realize that there are several pitfalls in the in­
terpretation of these tests, which can be classified at three levels 
(table I). 
Table I.Problems with interpretation of innune complex assays 
Technical difficulties 
In vitro result may not represent in vivo situation 
Positive test may be epiphenomenon of underlying disease 
Technical problems can clearly cause difficulties in the interpretation 
when the C1q binding assay (ClqBA) is used. We describe in chapter 2 
how fibrinogen and heparin can cause false positive results in this as­
say. However, once this pitfall is recognized it can be circumvented 
relatively easily by using serum instead of plasma or, if this is not 
possible, by adding protamine sulphate to the plasma sample. A problem 
that cannot be solved easily is encountered in the immune complex as­
says used in the diagnosis of SLE. As already pointed out in chapter 1 
it is generally assumed that deposition in tissues of DNA-anti DNA im­
mune complexes from the circulation initiates the damage in this di­
sease. The high frequency of positive results in SLE sera, obtained 
with different IC-assays seems to support the central role of CIC in 
the pathogenesis of SLE. However, recent findings have raised serious 
doubts about the interpretation of the results of various IC-assays in 
SLE sera. We have found that anti-DNA antibodies can cause false posi-
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tive results in the Raji cell assay (RCA) ( chapter 4)· We could show 
that purified monomeric 7S anti-DNA binds to the cell membrane of the 
Raji cell. This even occurs after saturation of Fc- and complement re­
ceptors on the Raji cell with aggregated iimunoglobulins. This observa­
tion is in line with previous studies in which it was shown that anti-
nuclear antibodies can bind to Raji cells (3/4) even after removal of 
surface receptors with pronase (3). In addition to this, it was recent­
ly shown that also murine (5) and human (6) monoclonal anti-DNA antibo­
dies can bind to Raji cells. Therefore, the major auto-antibody present 
in the serum of SLE patients can cause false positive results, or at 
least suggest spuriously high levels of CIC. Results from other IC-
assays of SLE sera must also be interpreted with caution. The assays 
which yield, after the RCA, the highest incidence of positivity (78% 
and 58% respectively) are the ClqBA and the Clq solid phase assay 
(C1qSPA)(7). There is, however, a recent report in which it was demon­
strated with gel filtration, that antibodies to C1q might be respon­
sible for positive results in SLE sera with the ClqSPA (8) and there­
fore also in the ClqBA. Finally it should be mentioned that there are 
also IC-assays that in general fail to detect 1С in SLE sera. These as­
says are based on binding to Rf (7). So, taken together these findings 
have raised serious doubts about the pivotal role of CIC in the patho­
genesis of SLE manifestations. 
A second problem that is not specific for the diagnosis of immune com­
plex diseases but pertains also to many other disease states is the 
question as to whether the results obtained in the test tube correctly 
reflect the situation in vivo. This is most strikingly exemplified by 
our experience with the ClqBA as an indicator of circulating complexes 
in RA sera. The ClqBA is positive for 1С in 66 to 85% of RA sera 
(9-12), while in other assays based on Clq binding these sera were ne­
gative . Our study described in chapter 3 provided an explanation for 
this discrepancy, we found that in vitro igM-Rf forms a complex with 
IgG due to the presence of PEG. Removal of PEG resulted in complete 
dissociation of the complex. We concluded that the ClqBA erroneously 
suggested the presence of CIC in RA sera. 
In a comparative analysis carried out by the WHO (7), the test that 
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scored second in the detection of 1С in RA sera was the Raj i cell assay 
(RCA). However, as already mentioned, antinuclear antibodies, which are 
frequently present in RA sera, can cause false positive results in the 
RCA. When RA sera which lacked anti-nuclear antibodies were tested in 
the RCA all but one were negative (4). A third 1С assay that frequently 
yielded positive results in RA sera was the monoclonal Rf inhibition 
assay. However, polyclonal Rf present in RA sera, directly influences 
binding and renders this assay unsuitable for RA sera (7). 
Despite the fact that the assays used to detect immune complexes in se­
ra of patients with RA do not withstand critical scrutiny, the concomi­
tant presence of both the auto-antibody (Rf) and the antigen (immuno­
globulins) in the circulation of RA patients makes it very likely that 
1С can be formed in vivo. Furthermore, immunological analysis of joint 
fluid and iinnunohistological examination of synovium of affected joints 
in RA (13) seem to indicate that 1С formation in the arthritic lesions 
actually occurs. The affinity of the antibody and the concentrations of 
antigen and antibody will determine whether the equilibrium will be at 
the side of free antigen and free antibody or at the side of the com-
plexed form. The in vitro conditions of immune complex assays can easi­
ly alter the antibody avidity, resulting in a change of this equili­
brium, and therefore it remains uncertain whether they are a reliable 
reflection of the in vivo situation. Complement levels are usually nor­
mal in sera of RA patients. Because the detected complexes are able to 
bind C1q, complement consumption should occur at substantial complex 
concentrations. The fact that complement profiles in the serum are nor­
mal has been explained by assuming that the levels are the resultant of 
complex-induced complement consumption and increased synthesis of com­
plement components. Alternatively, it might also indicate that in vivo 
only minor amounts of complexes are formed. The absence of substantial 
levels of complement break-down products and the lack of CI activation 
in serum are in favour of the latter possibility (9,14,15). We propose 
that in patients with active RA without systemic involvement, circula­
ting auto-antibodies to IgG or to other autoantigens are complexed in 
amounts below a pathogenic threshold due to their low avidity. Local 
factors that exert an action similar to that of PEG in vitro, or a lo­
cal increase of antigen concentration or aggregation, might increase 
95 
the antibody avidity and favour immune complex formation at certain 
predilection sites. In RA the articular cavity might be such a site. In 
this case local complement activation should occur which is indeed evi­
denced by low complement levels in synovial fluids of inflamed joints 
in RA patients (16-19). This hypothesis explains the results obtained 
with a direct granulocyte phagocytosis test in patients with RA (20). 
In this assay the endocytosis of immunoglobulins and complement by gra­
nulocytes is an indication for the presence of CIC. A direct examina­
tion of the leukocytes obtained from the blood of RA patients was nega­
tive for IgG. However, in the leukocytes obtained from the synovial 
fluid of RA patients, inclusions of IgG, IgM, and C3 could be detected 
indicating the presence of inmune complexes in this fluid. Thus, the 
synovial fluid might provide the proper environment for complex forma­
tion intra-articularly between Rf and IgG with subsequent complement 
activation and inflammatory reactions. 
The third important question in the interpretation of the results of 
IC-assays is if in those cases where 1С are actually present in the 
circulation, they really act as pathogenic factors or if they just re­
present an eplphenomenon of the disease. One of the approaches to study 
the importance of circulating inmune complexes is to determine the 
clearance of intravenously injected, preformed immune complexes from 
the circulation and their subsequent tissue localization. In experimen­
tal animal studies it was found that both preformed stable immune com­
plexes and aggregated IgG were removed with equal effectivity from the 
circulation of normal mice and of the SLE strains MRL/1 and (NZBxNZW)FI 
(21-23 and own unpublished observations). Also, radiolabelled DNA in­
jected intravenously in SLE mice with high levels of anti-DNA antibo­
dies in their circulation, was rapidly cleared from the circulation by 
the liver and failed to deposit in diseased tissues such as glomeruli 
(24-27). Much confusion was caused by studies in human SLE patients in 
which heat damaged or IgG-sensitized autologous red blood cells were 
used as a model system for circulating inmune complexes. With this 
technique it was found that the clearance of treated RBC in SLE pa­
tients differed from that in normal controls (28-31). The defective 
clearance was correlated with disease activity and was found to be im­
proved after plasmapheresis treatment. On the basis of these results it 
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was concluded that the function of the mononuclear-phagocyte system in 
SLE patients was impaired, probably due to blockade by saturation with 
immune complexes from the circulation. It is however questionable 
whether IgG coated or heat damaged RBC can be regarded as a model for 
circulating immune complexes. Immunoglobulin-tagged or heat damaged 
erythrocytes are almost completely cleared by splenic phagocytes while 
immune complexes are cleared by the hepatic mononuclear-phagocyte sys­
tem (32). Studies m SLE mice provide more direct evidence against the 
hypothesis that a dysfunction in splenic uptake of RBC has any meaning 
for the clearance of immune complexes. In the SLE stram of NZB/W hy­
brid mice the clearance of well-defined stable immune complexes was 
normal (22) while in the same strain the clearance of IgG coated RBC 
was impaired (33). In a recent review Frank, who introduced the clea­
rance studies with IgG-coated erythrocytes in SLE patients, mentions 
the need for studies with probes that more closely resemble immune com­
plexes (32). If deposition of circulating inmune complexes is indeed 
not involved in the pathogenesis of SLE manifestations, which mechanism 
is then responsible for the ultimate tissue lesions? The recent disco­
very that anti-DNA antibodies can crossreact with several molecules 
other than DNA has provided exciting new possibilities. This crossreac-
tivity was first observed by the research group of Stollar and 
Schwartz, using cardiolipin and other phospholipids (34,35). Later on, 
the number of crossreactive epitopes has increased (see also chapter 7 ) 
and now includes proteins e.g. vimentin (36), polyamonic structures 
such as Cibacron blue F3GA (37,38) and dextran sulphate (39); cell sur­
faces of Raji cells (chapter 4; 5,6), Τ cells, В cells, erythrocytes 
(40), and thrombocytes (41). In addition to these crossreactions we 
found, as presented in this thesis in chapters 5 and 6, that polyclonal 
and monoclonal antx-DNA antibodies can crossreact with proteoglycans 
such as hyaluronic acid, chondroitin sulphate, and heparan sulphate. 
The possible implications of these observations for the pathogenesis of 
SLE are discussed in chapter 7. 
Our study throws serious doubts on the role of circulating immune com­
plexes in two diseases. In rheumatoid arthritis they may be a fact but 
their quantity is largely overestimated, because the majority is spu­
riously formed under the conditions of the in vitro assay, in SLE their 
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presence in the circulation is probably a fiction. It is more likely, 
that the actual tissue damage in this disease is initiated by direct 
binding of free anti-DNA antibodies to crossreacting antigenic targets 
fixed in the tissues. A critical analysis of the role of circulating 
immune complexes in other diseases, supposedly caused by these com-
plexes is clearly required, on the basis of the present evidence, how-
ever , it can already be stated that the classic paradigm of immune com-
plex-mediated disease needs radical re-evaluation. 
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SUMMARY 
The aim of this investigation was to elucidate the significance of cir-
culating immune complexes in the autoimmune diseases rheumatoid arthri-
tis (RA) and systemic lupus erythematosus (SLE). The first part of this 
thesis deals with the pitfalls of two of the most widely used immune 
complex assays: the C1q binding assay (ClqBA) and the Raji cell assay 
(RCA). The second part of this thesis deals with new developments in 
the research of anti-DNA antibody specificity. The cross reactivity of 
these antibodies with glycosaminoglycans is described, which might have 
important consequences for the immunopathogenesis of SLE· 
In Chapter I a short overview is given of the inflammatory potentials 
of inmune complexes and their potential role in the pathogenesis of RA 
and SLE. 
in Chapter II some pitfalls in the ClqBA were pointed out. When serum 
and plasma from the same donor were tested in the ClqBA, the plasma 
samples showed a significantly higher Clq binding activity than the se-
rum values, suggesting that clotting factors might interfere with the 
assay. Indeed addition of fibrinogen to serum resulted in a dose depen-
dent increase in Clq binding. Formation of complexes between radiola-
belled Clq and fibrinogen occurred due to the presence of polyethylene 
glycol (PEG). Furthermore, also the anti coagulant heparin interfered 
in the ClqBA, causing a dose dependent increase of d q binding. There-
fore, the presence of fibrinogen and heparin can cause false positive 
results in the ClqBA. This problem can be circumvented by adding Prota-
min sulphate to the plasma samples. Protamin sulphate antagonizes the 
interaction of heparin or fibrinogen with radiolabelled Clq, without 
interfering with the interaction of 125iciq with immune complexes. It 
is, however, preferable to use serum samples for this assay. 
In Chapter III sera from patients with rheumatoid arthritis, that gave 
a positive reaction in the ClqBA, were analyzed with sucrose gradient 
ultracentrifugation. With this technique immune complexes were not de-
monstrable, which suggested that no stable complexes were present in 
these sera. This discrepancy could be explained by the finding that PEG 
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used in the ClqBA enhanced the binding of rheumatoid factor IgM (Rf) 
to igG resulting in the in vitro formation of C1q binding Rf-IgG com-
plexes. Therefore the ClqBA detects predominantly Rf activity and erro-
neously suggests the presence of circulating inmune complexes in vivo. 
In Chapter IV human and murine SLE sera with high Raj i cell binding 
were analyzed with isokinetic sucrose gradient centrifugation. This 
technique failed to detect immune complexes in these sera and the Raj i 
cell binding activity was exclusively found in the 7S fraction of these 
gradients. By isolating anti-DNA antibodies we could demonstrate that 
7S anti-DNA antibodies can bind directly to Raj i cells even after satu-
ration of membrane bound complement and Fc receptors with aggregated 
IgG. It is concluded that the Raj i cell assay is not suitable for de-
tection of immune complexes in SLE sera containing anti-DNA antibodies. 
In Chapter V the cross reactivity is described of anti-DNA antibodies 
with the glycosaminoglyeans hyaluronic acid and chondroitin sulphate. 
The anti-glycosaminoglyean titers correlated significantly with the 
anti-DNA titer in the tested human SLE sera (n=10). Normal human serum 
and sera from patients with RA, thyreoiditis, or mixed connective tis-
sue disease reacted neither with glycosaminoglycans nor with DNA. That 
the reactivity to these glycosaminoglycans in these SLE sera was due to 
anti-DNA antibodies could be proven by isolation of polyclonal anti-DNA 
antibodies from these sera through affinity chromatography either with 
oligo dT cellulose or cibacron blue F3GA sepharose. These purified 
anti-DNA antibodies reacted with DNA as well as with hyaluronic acid. 
This crossreactivity was confirmed with a monoclonal anti-DNA antibody 
that reacted also with both glycosaminoglycans. 
In Chapter VI the cross reactivity is described of anti-DNA antibodies 
with heparan sulphate, the major glycosaminoglyean of the glomerular 
basement membrane. A significant correlation was found between the 
anti-DNA titer in SLE sera and the anti-heparan sulphate titer. By in-
hibition studies and by using monoclonal anti-DNA antibodies it could 
be proven unequivocally that the anti-heparan sulphate activity in SLE 
sera was caused by anti-DNA antibodies. Anti-DNA antibodies eluted from 
a human SLE kidney and from kidneys from MRL/1 mice reacted in vitro 
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also with heparan sulphate. 
In Chapter VII a brief review is given of the present evidence of the 
crossreactivity of anti-DNA antibodies. Based on these findings a new 
mechanism is proposed for the irmunopathogenesis of different SLE mani-
festations. Tissue or organ destruction is probably not caused by depo-
sition of circulating DNA-anti-DNA antibodies, but by a direct binding 
of anti-DNA antibodies to fixed, crossreacting antigens in these tis-
sues or organs. 
The results of the studies presented in this thesis lead to the conclu-
sion that the hypothesis of a pathogenic role of circulating inmune 
complexes needs to be re-evaluated (Chapter VIII). 
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SAMENVATTING 
In dit onderzoek werd de rol en de betekenis nagegaan van circulerende 
immuuncomplexen voor de systemische autoimmuunziekten rheumatoide ar-
thritis (RA) en systemische lupus erythematodes (SLE). Het eerste deel 
van dit proefschrift beschrijft technische problemen die aanleiding 
kunnen zijn voor vals positieve resultaten van de twee meest gebruikte 
immuuncomplex testen: de Clq bindingstest (ClqBA) en de Raji cel test 
(RCA)· In het tweede deel van het proefschrift wordt de kruisreactivi-
teit van anti-DNA antistoffen met glycosaminoglycanen beschreven. Deze 
kruisreactiviteit heeft mogelijk belangrijke consequenties voor het in-
zicht in de immunopathogenese van SLE. 
In hoofdstuk I wordt een kort overzicht gegeven van de inflammatoire 
eigenchappen van immuuncomplexen en hun mogelijke betekenis voor de Pa-
thogenese van RA en SLE. 
In hoofdstuk II worden enige technische problemen van de ClqBA geanaly-
seerd. Bij het testen in de ClqBA van gelijktijdig verkregen serum- en 
plasmamonsters van dezelfde donor werd een beduidend hogere Clq bin-
dingsactiviteit gevonden in het plasmamonster dan in het serummonster. 
Dit deed vermoeden dat stollingsfactoren een rol zouden kunnen spelen 
in de uitslag van de test. Inderdaad resulteerde toevoeging van fibri-
nogeen aan serum in een dosis afhankelijke toename van de Clq binding. 
Dit bleek te berusten op de vorming van complexen tussen radioactief 
gelabeld C1q en fibrinogeen in aanwezigheid van polyethyleen glycol 
(PEG). Ook de aanwezigheid van héparine in de ClqBA veroorzaakte een 
dosis afhankelijke toename van de Clq binding via hetzelfde mecha-
nisme. De vals-positieve resultaten in de ClqBA door aanwezigheid van 
fibrinogeen en héparine kunnen voorkomen worden door toevoeging van 
protamine sulfaat aan de plasmamonsters, protamine sulfaat voorkomt de 
interactie tussen héparine of fibrinogeen met radioactief gelabeld Clq 
en heeft geen invloed op de binding van radioactief gelabeld C1q met 
immuuncomplexen. Het verdient echter de voorkeur om in de ClqBA serum-
monsters te gebruiken. 
In hoofdstuk III worden sera van patiënten met RA, met een positieve 
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uitslag in de ClqBA/ geanalyseerd met sucrose gradient ultracentrifuga-
tie. Met deze techniek waren geen imrauuncomplexen aantoonbaar, hetgeen 
deed veronderstellen dat er geen stabiele complexen in deze sera aanwe-
zig waren. Deze discrepantie met de ClqBA resultaten kon worden ver-
klaard door het feit dat in de aanwezigheid van PEG er een binding op-
trad van IgM rheumafactor (Rf) aan serum IgG, hetgeen resulteerde in de 
in vitro vorming van Clq bindende Rf-IgG complexen. Daarom toont de 
ClqBA vooral de aanwezigheid van Rf activiteit aan en suggereert ten 
onrechte dat in vivo circulerende immuuncomplexen aanwezig zijn. 
in hoofdstuk IV worden humane en muize SLE sera met hoge Raji cel bin-
ding geanalyseerd met behulp van isokinetische sucrose gradient centri-
fugatie. Met deze techniek konden geen imrauuncomplexen in deze sera 
aangetoond worden. De Raji cel bindingsactiviteit werd slechts gevonden 
in de 7S fractie van deze gradiënten. Door isolatie van anti-DNA anti-
stoffen kon worden aangetoond dat 7S anti-DNA antistoffen direct kunnen 
binden aan Raji cellen, zelfs na verzadiging van membraangebonden com-
plement en Fe receptoren met geaggregeerd IgG. Op grond van deze bevin-
ding moet geconcludeerd worden dat de RCA niet geschikt is voor het de-
tecteren van immuuncomplexen in SLE sera die anti-DNA antistoffen be-
vatten . 
In hoofdstuk V wordt de kruisreactiviteit beschreven van anti-DNA anti-
stoffen met de glycosaminoglycanen hyaluronzuur en chondroitine sul-
faat. De anti-glycosaminoglycaan titers correleerden significant met de 
anti-DNA titer in de geteste humane SLE sera. Normaal humaan serum en 
sera van patiënten met RA, thyreoiditis of "mixed connective tissue di-
sease" reageerden noch met glycosaminoglycanen noch met DNA. Dat de 
reactiviteit met deze glycosaminoglycanen in de SLE sera berustte op 
anti-DNA antistoffen kon worden aangetoond door zuivering van polyclo-
nale anti-DNA antistoffen uit deze sera met behulp van affiniteitschro-
matografie met oligo dT cellulose of cibacron blue F3GA sepharose. De 
op deze manier geïsoleerde anti-DNA antistoffen reageerden zowel met 
DNA als met hyaluronzuur. Deze kruisreactiviteit kon worden bevestigd 
met een monoclonale anti-DNA antistof, die ook met beide glycosamino-
glycanen reageerde. 
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In hoofdstuk VI wordt de kruisreactiviteit beschreven van anti-DNA an-
tistoffen met heparan sulfaat, het belangrijkste glycosaminoglycaan van 
de glomerulaire basaalmembraan. Er werd een duidelijke correlatie in 
SLE sera gevonden tussen de anti-DNA titer en de anti-heparan sulfaat 
titer. Door remmingsstudies en het gebruik van monoclonale anti-DNA an-
tistoffen kon ondubbelzinnig worden aangetoond, dat deze binding aan 
heparan sulfaat werd veroorzaakt door anti-DNA antistoffen. Anti-DNA 
antistoffen geëlueerd uit een humane SLE nier en uit nieren van MRL/1 
muizen reageerden in vitro eveneens met heparan sulfaat. 
In hoofdstuk VII wordt een kort overzicht gegeven van de huidige stand 
van zaken met betrekking tot het onderzoek naar de kruisreactiviteit 
van anti-DNA antistoffen. Op grond van deze bevindingen wordt een nieuw 
mechanisme voorgesteld voor de immunopathogenese van de verschillende 
ziekteverschijnselen van SLE. Weefsel- of orgaanbeschadiging wordt 
waarschijnlijk niet veroorzaakt door depositie van circulerende DNA-
anti-DNA antistoffen, maar door een directe binding van anti-DNA anti-
stoffen aan kruisreagerende antigenen aanwezig in diverse weefsels of 
organen. 
Op grond van de resultaten van dit onderzoek lijkt de conclusie gewet-
tigd, dat de veronderstelde pathogenetische betekenis van circulerende 
immuuncomplexen kritisch gereëvalueerd dient te worden (hoofdstuk 
VIII) . 
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STELLINGEN 
I 
De Clq bindingstest is met geschikt voor het aantonen van immuuncom-
plexen in sera van patiënten met rheumatoide arthritis indien rheuma-
factor IgM in deze sera aanwezig is. 
Dit proefschrift 
II 
De Raji-cel test is ongeschikt om immuuncomplexen te bepalen in sera 
die anti-DNA antistoffen bevatten. 
Dit proefschrift 
III 
De aanwezigheid van fibrinogeen in plasma kan een vals positief resul-
taat in de Clq bindingstest veroorzaken. 
Dit proefschrift 
IV 
Anti-DNA antistoffen kunnen zich binden aan glycosaminoglycanen. De be-
tekenis van deze kruisreactiviteit voor de pathofysiologie van auto-
immuunziekten dient nader onderzocht te worden. 
Dit proefschrift 
V 
Het is noodzakelijk om bij patiënten die plasmaferese zullen ondergaan 
wegens een cryoglobullnemie een centrifugekamertemperatuur te kiezen 
die ruim boven de temperatuur ligt waarbij cryoprecipltatie in het pa-
tiëntenserum ontstaat. 
VI 
Eiwitbepalingen met behulp van nephelometrie in sera van patiënten met 
cryoglobulinemie zijn niet betrouwbaar. 
VII 
Een defect in de klaring van met IgG beladen erythrocyten door het mo-
nonucleair-fagocyten systeem betekent niet dat ook de klaring van cir-
culerende immuuncomplexen gestoord is. 
VIII 
Het is verbazingwekkend hoe onzorgvuldig bij patiënten met systemische 
lupus erythematodes gezocht Is naar de aanwezigheid van het antigeen 
DNA in de circulatie, in circulerende immuuncomplexen en in de weefsel-
deposities. 
IX 
De experimenten van Sano en Morimoto suggereren ten onrechte dat DNA 
alleen in sera van patiënten met systemische lupus erythematodes aanwe-
zig is en niet in sera van normale individuen. 
Sano en Morimoto, J.Immunol. 126: 538-539 (1981) 
X 
De aanwezigheid van anti-DNA antistoffen in de huid van SLE patiënten 
zou verklaard kunnen worden door een directe binding van deze anti-DNA 
antistoffen aan dermatan sulfaat. 
XI 
Bij de interpretatie van experimenten waarin antistof een remmende wer-
king uitoefent, dient zorgvuldig te worden nagegaan in hoeverre deze 
remming veroorzaakt kan zijn door het Fc-gedeelte van de antistof, in 
plaats van door specifieke interactie met een bepaald antigeen. 
J. Neppert, et al. Eur.J.Immunol. 15: 559-563 (1985) 
XII 
Het uitblijven van expressie van klasse II antigenen van het major his-
tocompatibility complex op vaatendotheel bij muizen na systematische 
toediening van gamma-interferon, is geen afdoend bewijs dat deze stof 
In vivo niet dit effect heeft, aangezien lokale produktie en afgifte 
van gamma-interferon door T-lymfocyten kan leiden tot concentraties van 
dit eiwit in de micro-omgeving van de endotheelcellen die aanzienlijk 
hoger zijn dan die in de bloedbaan. 
M. Skoskiewicz, et al. J.Exp.Med. 162: 1645-1661 (1985) 
XIII 
Behalve de poging het aantal inbraken terug te dringen door middel van 
voorlichting over preventie aan burgers, zou de (Nijmeegse) politie te-
gelijkertijd de (schuld)helers intensiever moeten gaan opsporen. 
XIV 
Niet alleen de auto dient periodiek gekeurd te worden op zijn deugde-
lijkheid, maar ook de automobilist. 
Nijmegen, 7 maart 1986 PETER FAABER 


